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JNTRODUCTION 
After the implementation of ,Council Directive 65/65/EEC,  75/318/F:EC  and 
75/319/EEC the most  important aspects of proprietary medici,nal  products are 
now  subject matter of common  regulation in the nine Member  states.  The  main 
purpose of suQh  regulation is to safeguard public health while at the same 
time ensuring that the development  of the pharmaceutical industry and trE".de 
in medicinal products within the  Cornnnmi ty will not be hindered. 
The  Directives regulate the following matters  : 
- conditions for marketing authorizations;  requirements for tests and trials 
to be carried out  on proprietary medicinal products; 
- manufacture and control of proprietary medicinal products; 
- labelling and package leaflets; 
- supervisory duties of national authorities; 
- the Committee for Proprietary Medicinal Products. 
Council Directive 78/25/F:EC which comes  into force  on  15 June 1979,  governs 
which colouring matters may  be added to medicinal products. 
The  Co  •ttee for Pro riet  Medicinal Products has been set up by Directive 
75  319  EEC  to ensure cooperative between the national competent  autb.o:r:i.ties, 
especially with a  view to obviating inconsistent decisions relating to 
marketing authorizations which are still issued at national" level. The  Ru.les 
of Procedure of the Committee are reproduced in this booklet.  The  Committee 
will issue an opinion as to whether a  particular product  complies with the 
conditions for the granting of a  marketing authorization  : 
- when  the holder of an initial marketing authorization applies for its 
extension to at least five other Member  states through the  Committee~ 
The  procedure to be applied by the applicant  is explained in the~ 
for applicants for marketing authorizations for proprieta;z medicinal 
products; 
-when inconsistent decisions are taken by Members  states in respect  of 
one and the same  product ; 
-when a  Member  state wishes,  in specific oases where the interest of the 
Community  is concerned,  to obtain the opinion of the  Committee before 
reaching a  decision. 
The  Committee for Proprietar,y Medicinal Products has  elaborated a  standard 
application form in accordance with which the  Committee wishes the parti-
culars in support  of applications for marketing authorizations to be 
presented. 
The  Council has clearly stated that the present level of harmonization 
merely represents one step towards achievement  of the objective of the free 
movement  of proprietar,y medicinal products.  Hence the  Commission  is obliged 
to submit  to the Co1.moil  before the 22 November  1980 a  proposal containing -6-
appropriate measures  leading towards the abolition of ~  remaining barrier 
to the free movement  of proprietar,y medicinal products. 
An  important task in this further development will lie with the Pharmaceut i-
cal Committee  set up by  Council  Decision 75/320/EEC.  The  duty of this 
Committee  which  consists of senior officials from the Member  states is to 
advise the-Commission  on  general questions  in the field of proprietar,y 
medicinal products. -7-
COtfiCIL  DIRECTIVE 
of 26  Januar,r 1965 
on the appro:rlma.tion of provisions laid down  by law,  regulation 
or administrative action relating to proprietary medicinal products 
( 65/  65/EEC) 
TKE  COUNCIL  OF  TKE  EUROPEAN  EC<!iOMIC  COMMUNITY, 
Having regard to the Treaty establishing the European Economic  Conmnmity, 
and in particular Article 100 thereof; 
Having regard to the proposal from the Commission; 
Having regard to the Opinion of the European Parliament  (1); 
Having regard to the Opinion of the Economic  and Social Committee  (2); 
Whereas the primary purpose of a:ny  ru.les  concerning the production and dis-
tribution of proprietary medicinal products must  be to safeguard pu.blic 
health; 
Whereas,  however, this objective must  be attained by means  which will not 
hinder the development  of the pharmaceutical industry or trade in medicinal 
products within the Cormmmity; · 
Whereas  trade in proprietary medicinal products within the Co:nmnmity  is 
hindered by disparities between certain national provisions,  in particular 
between provisions relating to medicinal products  (excluding substances or 
combinations of substances which are foods,  animal  feedin~uf':fs or toilet 
preparations);  and whereas  such disparities directly a:ffect the establish-
ment  and functioning of'  the common  market; 
Whereas  such hindrances DIIl.Bt  accordingly be removed;  and whereas this 
entails approximation of'  the relevant provisions; 
Whereas,  however,  such approximation can only be achieved progressively; 
and whereas priority must  be given to eliminating the disparities liable 
to have the greatest  e:ffect  on the :f'tmction:i.ng of' the common  market; 
(1)  OJ  No  84,  4e6el963,  P• l':fll/63 
(2)  OJ  No  1.58,  16el0el964,  P•  2508/64 -8-
HAS  ADOPTED  THIS  DIRECTIVE 
Chapter I 
Definitions and scope 
Article 1 
For the purposes of this Directive, the following shall have the meanings 
hereby assigned to them; 
1. Proprieta.r.y medicinal product  : 
~  rea.~prepared medicinal product  placed on the market under a  special 
name  and in a  special pack. 
2. Medicinal product  : 
~  substance or combination of substances presented for treating or prevent-
ing  disease in. human  beings or animals. 
Any  substance or combination of substances which may  be administered to 
human  beings or animals with a  view to making  a.  medical diagnosis or to 
restoring,  correcting or modifying physiolo'gica.l flmotions in human  beings 
or in animals is likewise considered a  medicinal product. 
3. St;tbstance  : 
~  matter irrespective of origin which may  be 
- human,  e.g. 
human  blood and human  blood products; 
- animal,  e.g. 
micro-organisms, whole animals,  parts of organs,  animal secretions, toxins, 
extracts, blood products,  etc.; 
- vegetable,  e.g. 
micro-organisms,  plants, parts of plants, vegetable secretions,  extracts, 
etc.; 
chemical,  e.g. 
elements, naturally occurring chemical materials and chemical  pr•oducts 
obtained qy  chemical  change or s.ynthesis. -9-
Article 2 
The  provisions of Chapters II to V shall apply only to proprietary medicinal 
products for human  use intended to be placed on the market  in Member  states. 
Chapter II 
Authorisation to place  propriet~ medicinal 
products on the market 
Article 3 
No  proprietary medicinal product  may  be placed on the market  in a  Member 
state unless an authorisation has been issued by the competent  authority of 
that Member  state. 
Article 4 
In order t.o  obtain an authorisation to place a  proprietary medicinal product 
on the market  as provided for in Article 3,  the person responsible for pla-
cing that product  on the market  shall make  application to the competent 
authority of the Member  state concerned. 
The  application shall be  a~companied by the following particulars and 
documents  :  ·· 
1. Name  or corporate name  and permanent  address of the person responsible 
for placing the proprietary product  on the market  and, where applicable, 
of the manufacturer. 
2. Name  of the proprietary product  (brand name,  or common  name  together with 
a  trade mark or name  of the manufacturer,  or scientific name together 
with a  trade mark or name  of the manufacturer). 
3. Qualitative and quantitative particulars of all the constituents of the 
proprietary product  in usual terminology,  but  excluding empirical chemical 
formulae,  with mention of the international non-proprietary name  recommended 
by the World Health Organisation where  such name  exists. 
4. Brief description of the method of preparation. 
5•  Therapeutic indications,  contra-indications an.d  side-effects. 
6. Posology,  pharmaceutical form,  method and route of administration and 
expected shelf life if less than three years. 
r•  Control methods  employed by the manufacturer (analysis and assay of the 
constituents and of the finished product,  special tests, e.g. sterility 
tests, tests for the presence of p,yrogenic substances, the presence of 
heavy metals,  stability tests, biological and toxicity tests). - 10-
B.  Results of  : 
- p~sico-chemical, biological or microbiological tests; 
- pharmacological and toxicological tests; 
- clinical trials. 
However  : 
a)  a  List  of published references relating to the pharmacological tests, 
toxicological tests and clinical trials may  be substituted for the rele-
vant test results in the case of : 
i)  a  proprietary product with an established use,  which has been 
adequately tested on  human beings so that its effects,. including 
side-effects, are already known  and are included in the published 
references; 
ii)  a  new  proprietary product,  in which the combination of active 
constituents is identical with that of a  known  proprietary product 
with an established use; 
iii) a  new  proprietary product  consisting solely of known  constituents 
that have been used in combination in comparable proportions in 
adequately tested medicinal products with an established use; 
b)  In the case of a  new  proprietary product  containing known  constituents 
not hitherto used in combination for therapeutic purposes,  references 
to published data may  be substituted for the tests of such constituents. 
9.  One  or more  specimens or moCk-ups  of the sales presentation of the 
proprietary product, together with a  package  leaflet where  one is to be 
enclosed. 
10. A document  showing that the manufacturer is authorised in his own 
country to produce proprietary products. 
11.  Any authorisation obtained in another Member  state or in a  third country 
to place the relevant proprietary product  on the market • 
Article 5 
The  authorisation provided for in Article 3 shall be refused if, after 
verification of the particulars and documents  listed in Article 4,  it proves 
that the proprietary medicinal product  is harmful in the normal conditions of 
use,  or that its therapeutic efficacy is lacking or is insufficiently substan-
tiated b,y  the applicant,  or that its qualitative or quantitative composition 
is not  as declared. 
Authorisation shall likewise be refused if the particulars and documents 
submitted in support  of the application do  not  comply with Article 4. - ll-
Article 6 
The  competent  authorities of Member  States may  refuse to authorise the 
placing on  the market  of a  proprieta~ medicinal  product for use as a 
contraceptive  where the sale of  proprieta~ products  intended principally 
for such purposes is prohibited under their laws. 
Article 7 
Member  States shall take all appropriate measures to  ensure that the proce-
dure for granting an authorisation. to place a  proprieta~ medicinal product 
on  the market  is completed within 120 days  of the date of  submitting the 
application. 
In  exceptional cases this time  limit  may  be  extended for a  futher ninety 
days.  The  applicant  shall be notified of such extension before the  expi~ 
of the initial time limit. 
Article 8 
Member  States shall take all appropriate measures to  ensure that the holder 
of an authorisation furnishes  proof that the controls have been carried out 
on  the finished product  in accordance with the methods  described by the 
applicant  pursuant to  item 7 of the second paragraph of Article 4• 
Article 9 
Authorisation shall not  affect the civil and  criminal liability of the 
manufacturer and,  where applicable,  of the person responsible for placing 
the  proprieta~ medicinal product  on  the market. 
Article 10 
Authorisations shall be valid for five years and shall be  renewed for five-
year periods,  on  application by the holder within the three months  preceding 
expi~. 
Chapter III 
Suspension and revocation of authorisation to market 
proprieta~ medicinal products 
Article 11 
The  competent  authorities of the Member  States shall suspend or revoke an 
authorisation to place a  proprieta~ medicinal product  on the market where 
that product  proves to be harmful in the normal  conditions of use,  or where 
its therapeutic efficaqy is lacking,  or where  its qualitative and quantita-
tive composition is not  as declared.  Therapeutic efficaqy is lacking when - 12-
it is established  that therapeutic results cannot  be obtained with the 
proprietar,y product. 
An  authorisation shall also be suspended or revoked where the particulars 
supporting the application as provided for in Article 4 are fo1.md  to be 
incorrect,  or when the controls on the finished p~duct referred to in 
Article 8 have not been carried out. 
Article 12' 
All decisions taken pursuant to Articles 5,  6 or 11 shall state in detail 
the reasons  on which they are based.  A decision shall be notified to the 
party concerned,  who  shall at the same  time be informed of the remedies 
available to him 1.mder the laws  in force and of the time limit allowed for 
the exercise of such remedies. 
Authorisations to place a  proprietar,y.product  on the market  and decisions 
to revoke authorisations shall be published by each Member  state in the 
appropriate official publication. 
Chapter IV 
Labelling of proprietar,r medicinal products 
Article 13 
The  following particulars shall appear on containers and outer packages of 
proprietar,y medicinal products  : 
1. Name  of the proprietar,r product which may be a  brand name,  or a  common 
name  together with a  trade mark or name  of the manufacturer,  or a  scienti-
fic name  together with a  trade mark or name  of the manufacturer. 
2. Next  to the name  of the proprietar,y product,  a  statement  of the active 
constituents expressed  qualitative~ and  quantitative~ per dose-unit  or 
as a  percentage,  according to the pharmaceutical form.  The  international 
non-proprietar,y names  recommended by the World Health Organisation shall 
be used wherever they exist  • 
3. Reference number for production identification (manufacturer's batch 
number). 
4•  Number  of the authorisation to place the proprietar,y product  on the market. 
5.  Name  or corporate name  and permanent  address of the person responsible for 
placing the proprietar,y product  on the market  and,  where applicable,  of the 
manufacturer. 
6. Method of administration. 
7.  Expiry date for proprietary products with a  shelf life of less than three 
years. - 13-
B.  Special storage precautions, if ~· 
The  pharmaceutical form and the contents by weight,  by volume or by number of 
dose-units need only be  shown  on the outer packages. 
Article 14 
In the case of ampoules,  the particulars required 1mder the first  paragraph 
of Article 13  shall be given on the outer packages.  However,  on the actual 
containers,  only the following particulars are required  : 
- name  of the proprietary medicinal product; 
- quantity of active constituents; 
- route of administration; 
- expiry date. 
Article 15 
As  regards  small single-dose containers,  other than ampoules,  on which it is 
impossible to give the particulars mentioned in Article 14, the requirements 
of Article 13 shall apply only to the outer package. 
Article 16 
In the case of narcotics,  in addition to the particulars mentioned in 
Article 13,  a  special sign consisting of a  double red line shall appear on 
both the outer package and the container. 
Article 17 
Where there is no  outer package,  the particulars which  should feature  on 
such a  package pursuant to the preceding Articles shall be  shown  on the 
container. 
Article 18 
The  particulars mentioned in items  6,  7  and 8 of the first paragraph of 
Article 13 shall appear on the outer package and on the container of pro-
prietary medicinal products in the  language or languages of the co1mtry 
where they are being placed on the market • 
Article 19 
The  prov1s1ons of this Chapter shall not  prevent the particulars required 
by rules other than those to which this Directive relates from being given 
on outer packages or on containers. - l<t-
Article 20 
Where  the prov1s1ons  of this  Chapter are not  observed and an order addressed 
to the person concerned has remained without  effect, the competent  authorities 
of the Member  States may  suspend or revoke the authorisation to place the 
proprietar.y medicinal product  on the market. 
All decisions taken in pursuance of the preceding paragraph shall state in 
detail the reasons  on which they are 'based.  A  decision shall be notified 
to the party concerned,  who  shall at the  same  tim~ be  informed of the 
remedies available to him under the  laws  in force and of the time limit 
allowed for the exercise of such  remedies. 
Chapter  V 
General  and final provisions 
Article 21 
An  authorisation to  market  a  proprietar.y medicinal product  shall not be 
refused,  suspended or revoked  except  on the grounds  set  out  in this 
Directive. 
Article  22 
Member  States shall put  into force the  meas·ares needed in order to  comply 
with this Directive within eighteen months  of its notification and shall 
inform the  Commission forthwith. 
Article  23 
Member  States shall ensure that they comrrnm:icate to the  Commission the text 
of the main  provisions of national law which they adopt  in the field covered 
by this Directive. 
Article  24 
In the five years following the notification mentioned in Article 22,  the 
rules for which  provision is made  in this D:Lrective  shall be applied pro-
gressively to  proprieta~ medicinal  productB  covered by an authorisation to 
place  on the market by virtue of previous provisions. - 15-
Article 25 
This Directive is addressed to the Member  States. 
Done  at  Br-ussels,  26  January 1965. 
For  he  Council 
M.  CO  DE  MURVILLE - 17-
9.6. 75  Official journal of the European Communities  'No L 147/1 
COUNCIL DIRECOVE 
of 20 May 1975 
on the approximation of the laws of Member States  relating to analytical, pharmaco-
toxicological and clinical standards and protocols in respect of the testing of proprietary 
medicinal products 
(75/318/EEC) 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having  regard  to  the  Treaty  establishing  the 
European  Economic  Community,  and  in  particular 
Article 100 thereof; 
Having regard to the proposal from  the Commission; 
Whereas  the  approximation  begun  by  Council 
Directive  65/65/EEC (1)  of  26  January  1965  on  the 
approximation  of  provisions  laid  down  by  law, 
regulation  or  administrative  action  relating  to' 
proprietary  medicinal  products  should  be  continued 
and  the  implementation  of the  principles  laid down 
in that Directive should be ensured; 
Whereas  among  existing  disparities  those  relating 
to the  control of proprietary medicinal  products  are 
of fundamental  importance and point 8 of  Article 4, 
second paragraph of the said  Directive  requires  that 
applications for  authorization to  place  a proprietary 
medicinal  product  on  the  market  should  be 
accompanied  by  particulars  and  documepts  relating 
to the  results  of tests  and  trials  carried ·out  on  the 
product concerned; 
Whereas standards and protocols for the performance 
of tests  and trials on proprietary medicinal  products 
are  an  effective  means  of control  of these  products 
and  hence  of  protecting  public  health  and  can 
(1)  OJ No 22, 9. 2. 1965, p. 369165. 
facilitate  the  movement  of  these  products  by  laying 
down  uniform  rules  applicable  to  tests  and  trials, 
the  compilation  of  dossiers  and  the  examination  of 
applications; 
Whereas  the  adoption  of  the  same  standards  and 
protocols  by  all  the  Member  States  will  enable  the 
competent authorities  to  arrive  at their decisions  on 
the  basis  of uniform  tests  and  by  reference  to  uni-
form  criteria and  will  therefore  help  to avoid  differ-
ences in evaluation; 
Whereas  the  physico-chemical,  biological  or  micro-
biological  tests provided  for  in  point 8 of Article  4, 
second paragraph, of Directive 65/65/EEC are closely 
related to points 3, 4, 6 and 7 of  th~ same paragraph 
and  it  is  therefore  necessary  to  specify  the  data  to 
be provided pursuant to these points; 
Whereas  the  quality  of  the  tests  is  the  essential 
consideration;  whereas  therefore  tests  carried  out in 
accordance with these  provisions must be  taken  into 
consideration  irrespective  of  the  nationality  of  the 
experts who  perform  them  or the  country  in  which 
they are carried out; 
Whereas  the  concepts  of  'harmfulness'  and  'thera-
peutic  efficacy'  referred  to  in  Arricle  5  of  Directive 
65/65/EEC can  only be examined  in  relation  to each 
other and have only a relative significance depending 
on  the  progress of scientific  knowledge  and  the  use 
fOr  which  the  propJjetary  medicinal  product  is - 18-
intended;  whereas  the  particulars  and  documents 
which  must  accompany  an  application  for  authoriz-
ation  to  place  a  proprietary  medicinal  product  on 
the  market  demonstrate  that  potential  -risks  are 
outweighed  by  the  therapeutic  efficacy  of  the 
product;  whereas  failing  such  demonstration,  the 
application must be rejected; 
Whereas  the  evaluation  of  'harmfulness'  and 
'therapeutic  efficacy'  may  be  modified  in  the  light 
of new discoveries and standards and protocols must 
be  amended  periodically to  take  account of scientific 
progress, 
HAS ADOPTED THIS DIRECTIVE : 
Article  1 
Member States shall take all  appropriate measures to 
ensure  that  the  particulars  and  documents  which 
must  accompany  applications  for  authorization  to 
place  a proprietary medicina:l  product on the market 
(marketing authorization), pursuant to points 3, 4, 6, 
7 and  8 of Article  4,  second  paragraph, of Directive 
65/65/EEC,  are  submitted  by  the persons  concerned 
in accordance with the Annex to this Directive. 
Where,  pursuant to point 8 (a)  and  (b)  of Article 4, 
second  paragraph,  of the  abovementioned  Directive, 
references  to  published  data  are  submitted,  the 
provisions of this Directive shall apply in like manner. 
Article 2 
Notwithstanding  the  provtstons  of  other  Directives 
on  proprietary  medicinal  products,  Member  States 
shall  take  all  appropriate  measures  to  ensure  that 
the  competent  authorities  examine  the  particulars 
and  documents submitred  in  support of applications 
for  marketing, authorization  in  accordance  with  the 
criteria of the Annex to this Directive. 
Article 3 
Member  States  shall  bring into force  the  provisions 
needed in order to comply with this Directive within 
18  months  of  its  notification  and  shall  forthwith 
inform the Commission thereof. 
Member  States  shall  ensure  that they  communicate 
to  the  Commission  the  text  of  the  main  provisions 
of national law which they adopt in the field covered 
by this Directive. 
Article 4 
This Directive is addressed to the Member States. 
Done at Brussels, 20 May 1975. 
For the Council 
The President 
R.RYAN - 19-
ANNEX 
PART! 
PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF 
PROPRIETARY MEDICINAL PRODUCTS 
A.  QUALITATIVE AND QUANTITATIVE 
PARTICULARS OF THE CONSTITUENTS 
The  particulars  and  documents  which  must  accompany 
applications  for  ma•keting  authorization,  pursuant  to 
point  3  of  Article  4,  second  paragraph,  of  Directive 
65/65/EEC  shall  be  submitted  in  accordance  with  the 
following requirements. 
1.  'Qualitative  particulars'  of  all  the  constituents  of  the 
proprietary  medicinal  product  shall  mean  the 
designation or description of: 
- the active ingredient(s); 
- the  constituent(s)  of the excipients,  whatever their 
nature  or  the  quantity  used,  including  colouring 
matter,  preservatives,  stabilizers,  thickeners, 
emulsifiers,  flavouring  and  aromatic  substances, 
etc.j 
the  constituents,  intended  to  be  ingested  or 
otherwise administered  to the  patient, of the outer 
covering  of  the  proprietary  medicinal  products -
capsules,  gelatine  capsules,  cachet  shells,  rectal 
capsules, etc. 
These  particulars  shall  be  supplemented  by  any 
relevant  data  concerning  the  container  and,  where 
appropriate, its manner of closure. 
2.  The 'usual  terminology',  to  be  used  in  describing  the 
constituents  of  proprietary  medicinal  products,  shall 
mean,  notwithstanding  the  application  of  the  other 
provisions  of  point  3  of  Article  4,  second  paragraph, 
of Directive 65/65/EEC: 
- in  respect  of  substances  which  appear  in  the 
European  Pharmacopoeia  or,  failing  this,  in  the 
national  pharmacopoeia  of  one  of  the  Member 
States, the main title at the head of the monograph 
in  question,  with  reference  to  the  ph,armacopoeia 
concerned; 
- in  respect  of  other  substances,  the  international 
non-proprietary name recommended  by  the World 
Health  Organization,  which  may  be  accompanied 
by  another non-proprietary name, or, failing  these, 
the  exact  scientific  designation;  substances  not 
having  an  international  non-proprietary  name  or 
an  exact  scientific  designation  shall  be  described 
by  a  statement of how and from  what they  were 
prepared, supplemented, where appropriate, by any 
other relevant details; 
- in  respect  of  colouring  matter,  designation  by  the 
'E'  code  assigned  to  them  in  a  future  Council 
Directive  on the approximation of the  rules  of the 
Member  States  concerning  the  colouring  matters 
authorized  for  use  in  proprietary  medicinal 
products. 
3.  In  order  to  give  'quantitative  particulars'  of  the 
active  constituents  of  the  proprietary  medicinal 
products,  it  is  necessary,  depending  on  the 
pharmaceutical form  concerned, to  specify  the weight, 
or  the  number  of  international  units,  either  per 
dosage-unit  or per  unit  of  weight  or volume,  of  each 
active ingredient. 
This information shall be  supplemented: 
- in  respect o(injectable preparations, by  the  weight 
of  each  active  ingredient  in  the  unit  container, 
taking  into  account  the  usable  volume  of  the 
product; 
- in  respect  of  proprietary  medicinal  products  to  be 
administered  by  drops,  by  the  weight  of  each 
active ingredient contained  in  the number of drops 
corresponding to an average dose; 
- in  respect  of  syrups,  emulsions,  granular 
preparations  and  other  pharmaceutical  forms  to 
be  administered  in  measured  quantities,  by  the 
weight  of  each  active  ingredient  per  measured 
quantity. 
Active  ingredients  present  in  the  form  of  compounds  or 
derivatives  shall  be  described  quantitatively  by  their 
total  weight,  and  if  necessary  or  relevant,  by  the  weight 
of  the  active  moiety  or moieties  of  the  mokcule  (in  the 
case  of  chloramphenicol  palmitate,  for  example,  the 
weight  of  the  ester  and  that  of  the  corresponding 
chloramphenicol shall be given). 
The biological  units  of  acti·1ity  of substances which  have 
not  been  defined  chemically,  and  on  which  there  is 
insufficient bibliographical information, shall be expressed 
in such a way  as  to provide unambiguous information on 
the activity of the substances. 
B.  DESCRIPTION OF METHOD OF PREPARATION 
The  'brief  description  of  the  method  of  preparation' 
accompanying the application for marketing authorization 
·pursuant  to  point  4  of  Article  <4,  second  paragraph,  of 
Directive 65/65/EEC,  ~hall be  drafted in  such a way  as  to 
sive an adequate synopsis of the nature of the operations 
employed. 
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For this purpose it  shall include at kast: 
mention of the  various  stages  of manufacture, so  that 
an  assessment  can  be  m;ldc  of  whether  the  processes 
employed  in  producing the pharmaceutical form  might 
have produced an adverse change in  the constitu~nts; 
in  the  case  of  continuous  manufacture,  full  details 
concerning  precautions  taken  to  ensure  the 
homogeneity of the final  product; 
the  actual  manufacturing  formula,  with  the 
quantitative  particulars of all  the  substances  used,  the 
quantities  of  excipients,  however,  being  given  in 
approximate  terms  in  so  far  as  the  pharmaceutical 
form  makes  this  necessary;  mention shall  be  made of 
any  substances  that  may  disappear  in  the  course  of 
manufacture; 
a  statement  of  the  stages  of  manufacture  at  which 
sampling  is  carried  out  for  in-process  control  tests, 
where  other  data  in  the  dowments  supporting  the 
application  show  such  texts  to  be  necessary  for  the 
quality control of the proprietary medicinal product. 
C. CONTROl. OF STARTING MATERIAI.S 
For  the  pupc>S"  of  this  paragraph,  'starting  materials' 
shall  mean  all  the  comtituents  of  the  proprietary 
medicinal  product  anJ,  if  necessary,  of  its  container,  as 
referred to in  paragraph A point 1, above. 
rhe  particulars  and  documents  accompanyin~  the 
:-~pplication for  marketing authorization pursuant to points 
7  and  8  of  Article  4,  second  paragraph,  of  Directive 
1\) 161/EEC  shall  include  the  results  of  the  tests  relating 
to quality control of all  the  constituents used.  These shall 
he submitted in  accordance with the following provisions. 
1.  Starting materials listed in  pharmacopoeias 
The  monographs  of  the  European  Pharmacopoeia  shall 
he  applicable to all  substances appearing in it. 
In  respect  of  other  substances,  each  Member  State  may 
require  observance  of  its  own  national  pharmacopoeia 
with regard to products manufactured in  its territory. 
Constituents  fulfilling  the  requirements  of  the  European 
Pharmacopoeia  or  the  pharmacopoeia  of  one  of  the 
Member  States  shall  be  deemed  to  comply  sufficiently 
with  point 7  "f Article  4,  second  paragraph, of Directive 
65/6.5/EEC.  In  this  case  the  description  of  the 
analytical  methods  may  he  replaced  by  a  detailed 
reference to the pharmacopoeia in  question. 
However,  where  a  starting  material  in  the  European 
Pharmacopoeia  or  in  the  pharmacopoeia  of  a  Member 
State  has  been  prepared  by  a  method  liable  to  leave 
impurities  not  mentioned  in  the  pharmacopoeia 
monograph these impurities and their maximum tolerance 
levels  must  he  declared  and  a  suitable  test  method 
advanced. 
Refer<•nce  to  ph.1rmaropoci"'  of  third  ro111ltrie'  may  he 
permitted  in  c"'e'  where  the  suhstance  is  dcsnihed 
neither  in  the  F.uropc;ln  Pharmacopoeia  nor  111  the 
national  pharmacopoeia  concerned;  in  that  cao.;c  the 
nwntJ~raph  shall  he  submitted,  accomp;mied  where 
necess:uy  hy  a  translation  for  which  the  applicant  will 
he  responsible. 
\.olourin~  matter  shall,  in  all  cases,  satisfy  the 
requirement\  of  a  future  Council  Dircaivc  on  the 
approximation  of  the  rules  of  the  Member  States 
c.:onccrning  the  colouring  m:Htcrs  authorized  for  USl'  in 
proprietary medicinal products. 
For routine  tests on each  batch of starting material, only 
that  part  of  the  pharmacopoeia  rctnin~ to  control  tests 
(purity  and  strengths)  shall  he  mandatory;  the  full  ran~c 
of identity  tests  need  not necessarily  he  performed  where 
those  that  have  heen  performed  permit  an  unamhi~uou.~ 
charactcritat!on.  In  this  case,  the  reference  to  the 
monograph  of the  pharmacopoeia  mentioned  above shall 
include details relating to this aspect. 
In  Cl<.;(·s  where  a  spccifitation  l"OrHaincd  in  a  monograph 
of  the  European  Pharmacopoeia  or  in  the  national 
pharmacnp<>ci:t  of  a  Memher State  might  he  insufficient 
to  ensure  the  quality  of  the  substance,  the  competent 
authorities  may  request  more  appropriate  specifications 
from  the  per\on  responsible  for  pt1cin~ the  product  on 
the market. 
2.  Starting materials not in a pharmacopoeia 
Constilucnts  which  arc  not  given  in  any  pharmacopoeia 
shall  he  described  in  the form  of a  monograph under the 
following headings: 
(a)  The  11ame  of the substa11ce,  meeting the  requirements 
of  paragr:1ph  A,  point  2,  shall  be  supplemented  by 
any trade or scientific synonyms; 
(b) the descriptio11  of the  substance, set down  in  a  form 
similar  to  that  used  in  a  descriptive  item  in  the 
European  Pharmacopoeia,  shall  be  accompanied  by 
any  necessary  explanatory  evidence,  especially  con-
cerning  the  molecular  structure  where  appropriate;  it 
must  in  such  a  case  be  accompanied  by  a  brief 
indication  of  the  method  of  synthetic  preparation. 
Where  substances  can  only  be  described  by  their 
method  of  preparation,  the  description  should  be 
sufficiently  detailed  to characterize a  substance which 
is constant both in  its composition and in its effects; 
(c)  methods  of  indentificatimz  may  be  described  in  the 
form  of  complete  techniques  as  used  for  production 
of the substance, and in the form  of tests which ought 
to be carried out as a  routine matter; 
(d)  purity tests  shall  be  described  in  relation  to  the  sum 
total  of  predictable  impurities,  especially  those  which 
may  have  a  harmful  effect,  and,  if  necessary,  those 
which, having regard to the combination of substance' 
to which  the application refeFs,  might adversely  affect 
the  stabi.lity  of  the  proprietary  medicinal  product  or 
distort analytical results; - 21-
(c)  the .1ssuy teclmiqw{s) must  he  descrihcd  in  sufficiently 
pre.-i'e  detail  so  as  to  he  reproducible  in  control 
te.r,,  carried  nut  at  the  request  of  the  competent 
authority; any  special  appar;ttus  and  equipment which 
may  he  used  shall  he  described  in  adequate  detail, 
P'"'ihly accompanied  by  a diagram.  The  formulae  of 
the  bhnratnry  reagents  shall  be  supplemented,  if 
necessary, by  the  method of preparation. 
The  standard  error  of  the  method,  its  reliability  and 
the  acceptability  limits of  the  results shall  be  spcci.fied 
.md, if necessary, explained. 
With  regard  to complex substances of plant or animal 
origin,  a  distinction  must  he  made  between  the  case 
where  multiple  pharmacolt,gii:al  effects  render 
chemical,  physical  or  biolog;cal  control  of  the 
principal  constituents  necessary,  and  the  case  ot 
,uh.r.mces  con<ainir.g  one  or  more  groups  of 
principles  having  similar  activity,  in  respect  of  which 
an  overall method of assay  may  be accepted; 
(f)  a11y  special  pruaut1o11s  that  may  be 11ecess.:Iry  during 
stora~e of  the  starting  material  and,  if  necessary,  its 
storag~ life shall be given. 
D.  CONTROl. TESTS CARRIED OUT AT AN 
INTFRMFOIATE STAGE  OF THE MANUFACTURING 
PROCESS 
The  particulars  and  documents  accompanying  an 
application for  n.arketing authorization; pursuant to po!nts 
7  and  R  of  Article  4,  second  paragraph,  of  Directive 
65/6S/EEC,  shall  include  particulars  relating  w  the 
product  control  tests  that  m3y  he  carried  out  at  an 
intermediate  stage  of  the  manufacturing  process,  with  a 
view  to  ensuring.  the  consistency  of  the  technical 
characteristics and the production process. 
These  tests  are  essential  for  checking  the  conformity 
of  the  proprietary  medicinal  product  with  the  formula 
when,  exceptionally,  an  applicant  proposes  an  an<tlytical 
terhnique  for  testing  rhe  finished  product  whkh  does 
nor  include  the  assay  of  all  the  active  ingredients  (or 
of  all  the  excipient  constituent'  subject  m  the  same 
rec;uirements as  the active ingredients). 
The  same  applie~  where  the  quality  control  of  the 
finished  product  depends  on  in-process  control  tests, 
particularly  if  the  substance  is  essentially  defined  by 
its method of preparation. 
E.  CONTROL TESTS ON THE FINISHED PRODUCT 
The  particulars  and  documents  accompanying  the 
application  for  marketing  authorization  · pursuant  to 
points  7  and  8  of  Article  4,  second  paragraph,  of 
Directive  65/65/EEC,  shall  include  particulars  relating 
to  control  tests  on  the  finished  product.  They  shall  be 
submitted in accordance with th~ following requirements. 
1.  General  characteristics  ~f the  various  pharmaceutical 
forms 
Certain  tests  of the  general  characteristics  of a  product 
which  can  be  carried  out  in  the  course  of  the 
manufacturing  process  shall  always  be  included  among 
the tests on the finished product. 
As  a  guideline,  and  subject  to  the  possible  future 
requirements  of  the  European  Pharmacopoeia  or  the 
national  pharmacopoeias  of  Member  States,  the  general 
characteristics  which  are  to  be  verified  for  various 
pharmaceutical forms are given at point S below. 
These  tests  shall,  wherever  appliCable,  relate  to  the 
control  of  average  weights  and  maximum  deviations,  to 
mechanical,  physical,  or  microbiological  tests,  organo-
leptic  characteristics,  such  as  clarity,  colour,  taste, 
physical  characteristics  such  as  denshy,  pH,  refractive 
index,  etc.  For  each  of  these  characteristics,  standards 
and  tolerances  must  be  specified  by  the  applicant  in 
each particular case. 
2.  Identification and assay of active ingredient(s) 
The  description  of  the  te.::hniques  for  analyzing  tht· 
finished  product  shall  set  out  in  sufficientlr  pre.:ist 
detail,  so  that  they  c~n  be  reproduced  readily,  th: 
methods  used  for  identification  and  assay  of  the  acti\"t 
ingredient(s)  either  in  a  representative  umple  from  th( 
production batch or in  a number of dosage-units analyzt'J 
individually. 
In  every  case,  the  methods  must  correspond to  the  state 
of  scientific  progress  at  the  time  and  give  details  and 
explanations  of  the  standard  errors  and  reliability  of 
the  analytical  method  and  also  of  maximum  acceptable 
deviations. 
In  certain  exceptional  cases  of  particularly  complex 
mixtures,  where  assay  of  active  ingredients  which  are 
very  numerous  or  present  in  very  low  amounts  would 
necessitate  an  intricate investigation difficult to carry  out 
in  respect  of  each  production  batch,  the  assay  of  one 
or  more  active  ingredients  in  the  finished  product  may 
be  omitted,  on  the  express  condition  that  su.:h  assay~ 
are  made  at  intermediate  stages  in  the  production 
process.  This  relaxation  may  not  be  extended  to  the 
characterization  of  the  substanca  concerned.  This 
simplified  technique  shall  be  supplemented  by  a  method 
of  quantitative  evaluation,  enabling  the  competent 
authority  to  have  the · conformity  of  the  proprietary 
medicinal  product  with  its  formula  verified  after  it  has 
been placed on the market. 
An  assay  of biological  activity  shall  be  obligatory  when 
physico-chemical  methods  cannot  provide  adequate 
information on the quality of the product. 
Where  the  particulars  given  in  paragraph  B  show  that 
a  significant  overage  of  an  active  ingredient  was 
employed in the manufacture of the proprietary medicinal 
product,  the  description  of  the  control  tests  on  the 
finished  product  shall  include,  where  appropriate,  the 
chemical  and,  if  ·nec:eSsary,  the  toxico-pharmacologic:~l 
investigation  of  the  changes  that  this  substance  has 
undergone,  and  possibly  the  characterization  or  assay 
of the degradation products. - 22-
3.  Identification and assay of excipient constituents 
In  so  far as  is  necessary,  the  constituents of the  excipient 
shall be subject at least to characterization tests. 
The  method  proposed  for  identifying  colouring  matters 
must  enable  a  verification  to  be  made  that such  matters 
appear  in  the  list  to  be  annexed  to  a  future  Council 
Qirective  on  the  approximation  of  the  rules  of  the 
Member  States  concerning  the  colouring·  matters 
authorized for use in  proprietary medicinal products. 
An  upper  limit  test  shall  be  obligatory  in  respect  of 
excipient  constituents  which  are  subject  to  rules  relating 
to  toxic  substances  or  which  are  being  used  as 
preservatives, while an  assay  shall  be obligatory in  respect 
of constituents liable to affect physiological functions. 
4.  Safety tests 
Apart  from  the  toxico-pharmacological  tests  submitted 
with  the  application  for  marketing  authorization, 
particulars  of  safety  tests  (abnormal  toxicity}  or  local 
tolerance  in  animals  shall  be  included  in  the  analytical 
particulars  wherever  such  tests  must  be  undertaken  as  a 
matter  of  routine  in  order  to  verify  the  quality  of  the 
product. 
5.  General  characteristics  of  finished  products  to  be 
verified  systematically,  depending  on  the  pharma-
ceutical form of each product 
The  following  requirements  are  given  as  an  indication 
and  without prejudice  to  any  future  requirements  of the 
European  Pharmacopoeia  or national  pharmacopoeias  of 
Member States;  for example, microbiological control tests 
of preparations for oral administration shall  be performed 
in  accordance  with  the  requirements  of  the  European 
Pharmacopoeia. 
Tablets  and  pills:  colour,  weight  and  acceptable 
vanat10ns  in  unit  weight;  if  necessary,  disintegration 
time with the method used to determine this. 
Coated  tablets:  colour,  disintegration  time  with  the 
method  used  to determine  this;  weight of finished  tablet; 
weight of core and acceptable variations in  unit weight. 
Capsules  and  gelatine  capsules:  colour,  disintegration 
time  with  the  method  used  to  determine  this; 
appearance  and  weight  of  content  with  acceptable 
variations in unit weight. 
Enteric-coated  preparations  (tablets,  capsules,  gelatine 
capsules,  granular  preparations}:  in  addition  to  the 
requirements  of  the  particular  pharmaceutical  form, 
resistance  time  in  an  artificial  gastric  medium,  with  the 
method  used  to  determine  this;  disintegration  time  in  an 
artificial  intestinal  medium,  with  the  method  used  to 
determine this. 
PreparatioiiS  tl'ith  special  protective  coating  (tahlcts, 
capsules,  gelatine  capsttlcs,  granttlar  preparations):  in 
addition  to  the  requirements  ·of  the  particular 
pharmacrutical  form,  verification  of  the  effectiven-ess  of 
the coating for the desired purpose. 
l'reparatio11s  with  gradual  release  of  the  active  pri11cif>[e: 
in  addition  to  the  requirements  of  the  particular 
pharmaceutical  f~rm,  requirements  relating  to  gradual 
release, with the method used to determine this. 
Cachets,  packets  and  sachets:  nature  and  weight  of 
contents and acceptable variations in  unit weight. 
lt~iectable  preparations:  colour,  volume  of  contenr.  and 
acceptable  variations  of  this  volu·me;  pH,  clarity  of 
solution,  size  limit· of  particulate  matter  in  the  case  of 
suspensions;  sterility  tests,  with  description  of  test 
methods;  except  in  special  cases,  in  respect  of 
preparations  to  be  administered  in  single  doses  of  10  ml 
or more, a pyrogen test with description of method. 
Ampoules  with  solid  co11tent:  quantity  of  product  per 
ampoule  and  permitted  variations  in  weight;  st<~rility 
requirements and tests. 
Ampottles to be taken orally:  colour, appearance,  volume 
of content and acceptable variations. 
Ointments,  creams,  etc.:  colour  and  consistency;  weight 
and  acceptable  margin  of variation;  nature  of container; 
in  certain cases microbiological control tests. 
Suspensimts:  colour;  where  settlement  occurs,  the  ease 
of re-suspendability. 
Emulsions: colour, type, stability. 
Suppositories and pessaries: colour, weight and acceptable 
variations  in  unit  weight;  melting  temperature:  or 
disintegration  time,  with  the  methods  used  to  determine 
these. 
Aerosols:  description  of container and  valve  with  details 
of  output;  particle  size-limit,  where  the  product  is 
in,tended to be inhaled. 
Collyria,  eye  ointments,  eye  lotiu•ts:  colour,  appearance, 
sterility  controls,  with  description  of  the  method  used; 
where  appropriate,  clarity  and  size  limit  of  particulate 
matter in the case of suspensions, pH determination. 
Syrups, solutions, etc: colour, appeJ' omce. 
F.  STABILITY  TESTS 
The  particulars  and  documen>'  accompanying  the 
application for marketing auth0101  .,;,)n pursuant to points 
6  and  7  of  Article  4,  second  paragraph,  of  Directive 
65/65/EEC  shall  be  submitted  in  accordance  with  the 
fo:llowing requirements: - 23-
A  description  shall  be  given  of ·the  investigations  by 
which  the  shelf  life  proposed  by  the  applicant  has  been 
determined. 
Where  a  finished  product  is  liable  to  give  rise  to  toxic 
degradation  products  the  applicant  must  declare  these 
and indicate characterization and assay methods. 
The  conclusions  shall  contain  the  results  of  analyses, 
justifying the  proposed shelf life  under normal, or, where 
appropriate, under special storage conditions. 
A  study  of  the  interaction  between  product  and 
container  shall  be  submitted  wherever  the  risk  of  such 
interaction  is  regarded  as  possible,  especially  where 
injectable  preparations  or  aerosols  for  internal  use  are 
concerned. 
PART2 
TOXICOLOGICAL AND PHARMACOLOGICAL TESTS 
The  particulars  and  documents  arcompanying  the 
application for  marketing authorization pursuant to point 
8  of  Article  4,  second  paragraph, of Directive  65/65/EEC 
shall  he  given  in  accordance  with  the  requirements  of 
Chapters I and II below. 
CHAPTER  I 
PERFORMANCE OF TESTS 
A.  INTRODUCTION 
The toxicological and pharmacological tests must show: 
1.  the  potential .  toxicity  of  the  product  and  any 
dangerous or undesirable toxic effects that may  occur 
under  the  proposed  conditions  of  use  in  human 
beings;  these  should  be  evaluated  in  relation  to  the 
gravity of the pathological condition concerned; 
2.  the  pharmacological  properties  of  the  product,  in 
both  qualitative  and  quantitative  relationship  to  the 
proposed  use  in  human  beings.  All  results  must  be 
reliable  and  of  general  applicability.  Whenever 
appropriate,  mathematical  and  statistical  procedures 
.;hall  be  used  in  designing  the  experimental  methods 
and in evaluating the results. 
Additionally,  it  is  necessary  for  clinicians  to  be  given 
information  about  the  therapeutic  potential  of  the 
product. 
B.  TOXICITY 
1.  Single dose toxicity (acute toxicity) 
Acute  toxicity  test  means  a  qualitative  and  quantitative 
study  of  the  toxic  reactions  which  may  ·result  from  a 
single administration of the active substance or substances 
contained  in  the  proprietary  medicinal  product,  in  the 
proportions  in  which  they  are  present  in  the  actual 
product. 
Wherever  practicable,  the  product  in  its  actual  phar-
maceutical  form  shall  be  subjected  to  an  acute  toxicity 
test. 
This study will  cover the symptoms observed,  including 
local  reactions.  Where  possible,  the LD• value  with  its 
fiducial  limits  (951/t)  will  be  determined.  The  period 
during  which  the  test  animals  arc  oberserved  shall  be 
fixed  by  the  investigator  and  shall  not  be  less  than  one 
week. 
The  acute  toxicity  test  must  be  carried  out  on  at  least 
two  mammalian  speCies  of  known  strain,  and  at  least 
two  different  routes  of  administration  shall  ncrmally  be 
used:  one  being  indentical  with  or  similar  to  that 
proposed for  use  in  human beings  and  the other ensuring 
systemic  absorption  of the  substance.  This determination 
must  be  carried  out  on  equal  numbers  of  male  and 
female animals. 
In  the case of active substances in  combination, the study 
must  be  carried  out  in  such  a  way  as  to check  whether 
or notpotenthtion or novel toxic effects occur. 
2.  Repeated  dose  toxicity  (sub-acute  or chronic  toxicity) 
Repeated  dose  toxicity  tests  are  intended  to  reveal  any 
physiological  and/or  pathological  changes  induced  by 
repeated  administration  of  the  active  substance  or 
combination of active substances under examination, and 
to determine how these changes are related to dosage. 
Generally, it is  desirable that two tests be  performed: one 
short-term, lasting two to four weeks, the other long-term. 
The duration of the latter shall depend on the conditjons 
of  clinical  use.  Its  purpose  shall  be  to  determine  by 
experiment the  non-toxic  dose  range  of the  product  and 
normally it shall last three to six months. 
In  respect  of  proprietary  medicinal  products  to  be 
administered  once  only  to  humans,  a  single  test  lasting 
two to four weeks shall be performed. 
If,  however,  having  regard  to  the  proposed  duration  of 
use in human beings, the investigator sees  fit to carry out 
experiments  of greater  or lesser  duration  than  indicated 
lfbove, he must give adequate reasons for doing so. 
Reasons should also be given for the dosages chosen. 
Repeated dose  toxicity  tests  shall  be  carried out on two 
specie ol mammals one of which must be a  non-rodent. 
The dlaice of route(s)  of administration  employed  shall - 24-
depend  on  the  intended  therapeutic  me  and  the 
possibilities  of  systemic  alw>rptinn.  The  method  and 
frequency of dosage shall  he  clearly stated. 
The  maximum  dMe  should  be  chosen  so  as  to  bring 
harmful  effects  to light.  The lower doses will  then  enable 
the animal's tolerance of the product to be determined. 
Wherever  possible,  and  always  in  experiments  on  small 
rodents,  the  design  of  the  experiment  and  the  control 
procedures  must  be  suited  to  the  scale  of  the  problem 
being  tackled  and  enahlc  fiducial  limits  to  be 
determined. 
The  evaluation  of  the  toxic  effects  shall  be  based  on 
observation  of  behaviour,  growth,  hJCmatological  and 
biochemical  tests,  especially  those  relating  to  the 
excretory  mechanism,  and  also  on  autopsy  reports  and 
accompanying  histological  data. The choice  and  range  of 
each  group  of  tests  will  depend  on  the  species  of  animal 
used  and the state oi scientific knowledge at the time. 
In  the  case  of  new  combinations  of  known  substances 
that  have  been  investigated  in  accordance  with  the 
provisions  of  this  Directive,  the  long-term  tests  may, 
except  where  acute  and  subacute  toxicity  tests  have 
demonstrated  potentiation  or  novel  toxic  effects,  be 
suitably  modified  by  the  investigator  who  shail  submit 
his  reasons  for  such  modification.  Substances  that  have 
been  shown  to  be  safe  by  wide  usage  over  at least  three 
years  in  clinical  treatment  of human  beings,  and  by  the 
result  of  controlled  trials  shall  be  treated  in  the  same 
way  as  known  substances  which  have  already  been 
investigated  in  accordance  with  these  standards  and 
protocols. 
An  excipient used  for  the first  time  in  the pharmaceutical 
field shall  be  treated like an  active ingredient. 
C.  FOETAL TOXICITY 
Thi• investigation  comprises a demonstration of the toxic 
and  e.specially  the  teratogenic  effects  observed  in  the 
issue  of  conception  when  the  substance·  under 
investigation  has  been  administered  to the  female  during 
pregnancy. 
Although  up  to  the  present  these  tests  have  had  only  a 
limited  predictive  value  in  regard  to  the  application  of 
the  results  to human  beings,  they  are  thought  to  provide 
important information where the results show effects such 
as  resorptions and other anomalies. 
Omission  of  these  tests,  either  because  the  proprietary 
medicinal  product will  not  normally  be  used  by  women 
capable  of  childbearing  or  for  other  reasons,  must  be 
adequately justified. 
The tests in  question shall  be  carried out on at !east two 
animal  species:  a  breed  of  rabbits  sensitive  to  known 
teratogenic  substances  and  rats  or  mice  (specifying  the 
strain) or, if appropriate, in  some other animal species. 
The  details  of  the  test  (number  of  animals,  amounts 
administered,  timing  of  administration  and  criteria  for 
evaluation  of  results)  shall  depend  on  the  state  of 
scientific  knowledge  at  the  rime  when  the  application  is 
lodged,  .111d  the  level  of  statistical  significance  that· the 
results mt"t attain. 
D.  EXAMINATION OF  REPRODUCTIVE FUNCTION 
If  the  results  of  other  tests  reveal  anything  suggesting 
harmful  effects  on  progeny  or  impairment  of  male  or 
female  reproductive  function,  this  shall  be  investigated 
hy  appropriate tests. 
E.  CARCINOGENICITY 
Tests to reveal  carcinogenic effects shall be essential: 
1.  in  respect  of  substances  having  a  close  chemical 
analogy  with  known  carcinogenic  or  cocarcinogenic 
compound\; 
2.  in  respect  of  substances  which  have  given  rise  to 
suspicious  changes  during  the  long  term  toxicological 
tests. 
Such  tests  may  also  be  required  in  respect  of substances 
to  be  included  in  proprietary  medicinal  products  likely 
to  be  administered  regularly  over  a  prolonged  period  of 
a patient's life. 
F.  PHARMACODYNAMICS 
This  heading  covers  the  variations  caused  by  the 
substance  in  the  functions  of  the  physiological  systems, 
whether  these  functions  are  normal  or  experimentally 
modified. 
This  study  shall  follow  two  distinct  lines  of  approach. 
Firstly,  the  actions  on  which  the  recommended 
application  in  therapeutic  practice  is  based  shall  be 
adequately  described.  The  results  shall  be  expressed  in 
quantitative  terms  using,  for  example, dose-effect  curves, 
time-effect  curves  etc.,  and  wherever  possible,  compared 
with data relating to a substance whose activity  is  known. 
Where  a  higher  therapeutic potency  is  being  claimed  for 
a  substance,  the  difference  shall  be  demonstrated  and 
shown to be statistically significant. 
Secondly,  the  investigator  shall  provide  a  general 
pharmacological  characterization  of  the  substance,  with 
special  reference to  collateral effectS.  In  general, the main 
functions  of  the  physiological  systems  should  be 
investigated.  The  depth  of  this  investigation  must  be 
increased  as  the  doses  liable  to  produce  side-effects 
approach  those  producing the  main  effect  for  which  the 
substance is being propos~d. 
The  experimental  techniques,  unless  they  are  standard 
procedures,  must  be described  in  such detail  as  to allow 
them  to  be  reproduced,  and  the  investigator  must - 25-
establish  their  validity.  The  experimental  rc~ult~  shall 
be  set  out  dearly  and,  when  relevant  to  the  test,  their 
statistical significance quoted. 
Unless  good  reasons  are  given  to  the  contrary,  any 
quantitative  modification  of  responses  resulting  from 
repeated  administration  of  the  substance  shall  be 
investigated. 
Tests  on  combinations  of  active  substances  may  be 
prol!'pted  either  by  pharmacological  premises  or  by 
ind•cations of therapeutic effect. 
In  the  first  case,  the  pharmacodynamic  study  shall 
demonstrate  those  interactions  which  might  make  the 
combination of value in therapeutic usc. 
In  the  second  case,  where  scientific  justification  for  the 
combination  is  sought  through  therapeutic  experimen-
tation,  the  investigation  shall  determine  whether  the 
effects  expected  from  the  combination  can  be 
demonstrated  in  animals,  and  the  importance  of  any 
collateral effects shall at least be mvestigated. 
If a  combination  includes  a  novel  active  substance,  the 
latter must previously have been studied in  depth. 
G.  PHARMACOKINETICS 
Pharmacokinetics  means  the  study  of  the  fate  of  the 
active  substance  within  the  organism,  and  covers  the 
study  of  the  absorption,  distribution,  biotransformation 
and elimination of the substance. 
The  study  of  these  different  phases  may  be  carried  out 
both by  means of physicai, chemical or biological methods, 
and  by  observation  of  the  actual  pharmacodynamic 
activity of the substance itself. 
Information  on  distribution  and  elimination  shall  be 
necessary  in  all  cases  where  such  data  arc  indispensable 
to  determine  the  dosage  for  humans,  and  in  respect  of 
chemotherapeutic  substances  (antibiotics, ·  etc.)  and 
substances  whose  use  dep~nds  on  their  non--
pharmacodynamic  effects  (e. g.  numerous  diagnostic 
agents etc.) 
Pharmacokinetic  investigation  of  pharmacologically 
active substances is desirable. 
In  the  case  of  new  combinations  of  knoV~<n  substances 
which  have  been  investigated  in  accordance  with  the 
provisions  of this  Directive pharmacokinetic studies  shall 
not  be  required,  if  the  toxicity  tests  and  therapeutic 
experimentation  justify  their  omission.  The  same  applies 
to  substances that have been shown to be efficaceous and 
safe  by  wide  usage  over  a period  of at  least'  three  years 
in  the  clinical  treatment  of  human  beings  and  by 
controlled trials. 
H. PRODUCTS FOR TOPICAL USE 
Where  a  proprietary  medicinal  product  is  intended  for 
topical usc  systemic absorption must be  investigated, due 
account  also  beina  taken  of  the  pouible  UIIC  of  the 
product  on  broken  akin.  Only  if  it  is  proved  that 
systemic  absorption  under  these  conditions  is  negligible 
may  repeated  dose  systemic  toxicity  tests,  foetal  toxicity 
tests  and  studies  of  reproductive  function  be  omitted. 
If,  however,  systemic  absorption  is  demonstrated  during 
therapeutic  experimentation,  toxicity  tests  shall  be 
carried  out  on  animals,  anti  where  necessary,  foetal 
toxicity tests. 
In  all  cases  tests  of  local  tolerance  after  repeated 
application  shall  be  carried  out with  particular care  and 
include  histological  examinations;  the  possibility  ot 
sensitization  shall  be  investigated  and  any  carcinoaenic 
potential investigated in  the  cases  referred to in paragraph 
E. 
CHAPTER II 
PRESENTATION OF PARTICULARS AND 
DOCUMENTS 
As  in  all  scientific  work, the  dossier  of toxicological  and 
pharmacological tests shall be arranged as follows: 
(a)  an  introduction  dcLning  the  sub;ect  accompanied 
possibly by references to published data; 
(b) a  detailed  expcrimen:al  protocol  giving  a  description 
of  the  methods,  apparatus  and  materials  used,  details 
of  the  species,  and  the  breed  and  strain  of  animals, 
where  they  Were  obtained, ·their  number  and  the 
conditions  under  which  they  were  housed  and  fed, 
stating,  inter  alia,  whether  they  were  specific  patho· 
gcn-free  (SPF)  or  not;  omission  of  any  of  the  tests 
listed above shall be explained; 
(c)  all  the  important results  obtained, whether  favourable 
or unfavourable. The original da:a should be described 
in  sufficient detail  to allow  the  results  to  be  critically 
evaluated  independently  of  their  interpretation  by  the 
author.  By  way  of  explanation  and  illustration,  the 
results ·may  be  accompanied  by  rcproductlons  of 
kymographic charts, microphotographs, etc.; 
(d) a statistical analysis of the results, where such  is  called 
for  by  the  test  programme,  and  variance  within  the 
data; 
(e)  an  objective discussion of  the results obtained, leadina 
to condus:ons on  the toxicological and pharmacologi-
cal  properties  of  the  substance,  on  its  aafety  margins 
in the  animal and its possible side-effects, on its  fields 
of  application, on  its  active  dose  levels  and  any  pos-
sible incompatibilities; 
(f)  all  information  necessary  to  acquaint  the  clinician  as 
fully  as  possible  with  the  potential  of  the  proposed 
proprietary  medicinal  product.  The  discussion  shall 
be  supplemented  by  suggestions  as  to  pouible 
treatment for acute toxic. reactions and any side-effects 
that may occur in  human beings; 
(&)  1  aummary  toaether  with  preci~e  rcfen:nm  to 
publiahed data. - 26-
PART  3 
CLINICAL TRIALS 
The particulars and documents accompanying applications 
for  marketing  authorizations  pursuant  to  point  8  of 
Article  <second paragraph, of  Directive  65/65/FF.C:  shall 
be  submitted  in  accordance  with  the  provisions  of 
Chapters I and II below. 
CHAPTER  I 
CONDUCT OF TRIALS 
I.  Clinical  mals  must  always  he  preceded  hy  adequate 
pharmacological and toxicological  tests, carried out on 
animals  in  accordance  with  the  requirements  of  this 
Directive  relevant  to  such  tests.  The  clinician  must 
acquaint himself with the conclusions drawn from  the 
pharmacological  and  toxicological  studies  and  hence 
the  applicant  must  provide  him  with  the  complete 
pharmacological and toxicological reports. 
2.  Clinical  trials  must  he  carried  out  in  the  form  of 
'controlled clinical  trials'. The design  of the trials  will 
vary  from  case to case and  also  will  depend on ethical 
con~iJerations;  thus  it  may,  in  some  instances,  he 
more  pertinent  to  compare  the  therapeutic  effect  of 
a  new  proprietary  medicinal  product  with  that of an 
estahlishe<f  medicinal  product  of  proven  therapeutic 
value rather than with the effect of a placebo 
l.  As  far  as  possible, and  particularly in  trials where the 
effect  of the  product cannot  he  objectively  measured, 
the  'double  blind'  method  of  controlled  study  should 
he  used. 
4.  If  statistical  methods  arc  necessary  to  determine  the 
therapeutic  effect,  the  criteria  upon  which  the  trial 
is  based  must  he  sufficiently  precise  to  permit  a 
statistical  analysis  to  he  undertaken.  Inclusion  of  a 
large  number  of  patients  in  a  trial  must  not  he 
regarded  as  an  adequate  substitute  for  a  properly 
controlled trial. 
CHAPTER  II 
PRESENTATION OF PARTICULARS AND 
DOCUMENTS 
I.  The  clinical  particulars  to  be  provided  pursuant  to 
point  8  of  Article  4,  second  paragraph,  of  Directive 
65/65/EEC must enable a sufficiently well-founded and 
scientifically valid opinion to be formed as to whether 
the  proprietary  medicinal  product  satisfies  the  criteria 
go\'erning  the  granting  of  a  1n~ukcting  :~uthorit.ation. 
Con~rqucntly,  ;tn  cc,'>cntial  requirement  i{\  rh.u  the 
results  of  all  clinical  trials  should  he  mmmllnic.ncd, 
both f;wourahle ;tnd unfavourable. 
2.  The  n·,ult, of  the  trials  shall  he  presented  in  accord· 
ance with the following scheme: 
A.  PHARMACOLOGICAL PARTICULARS 
(Clinical pharmacology) 
1.  Wherever  pos•.ihlc  particulars  shall  he  given  of  th<' 
results of: 
(a)  tcsto.;  dcmon~.;trating pharmacological actions; 
(h) tests  demonstrating  the  pharmacodynamic  mech-
anism' underlying the therapeutic effect; 
(c)  tests demonstrating biotransformation and th<·  main 
phannacokinetic processes. 
Total  or  partial  omission  of  these  data  must  he 
explained. 
Should  unexpected  results  occur during  the  course of 
the  teMs,  further  preliminary  toxicological  and  ph:u-
macological  tests  on  animals  must  he  undertaken  ;tnd 
reviewed. 
2.  If  the  proprietary  medicinal  product  is  intended  for 
long-term  administration,  particulars shall  be  given of 
any modification of the pharmacological action follow· 
ing repeated administration. 
.l.  If  the  product  is  normally  to  be  administered 
concomitantly  with other  medicinal  products, particu-
lars  shall  be  given  of  joint  administration  tests 
performed  to  demonstrate  possible  modification  of 
the pharmacological action. 
4.  All  side-effects noted during the tests shall be described 
individually. 
B.  CLINICAL PARTICULARS 
l. Individual case histories - Clinical records 
Particulars of ~linical trials  must contain sufficient detail 
to allow  an objective  judgment to be made. As a  general 
rule,  these  trials  should be carried out in a  medical care 
establishment. - 27-
The aim  of the  trials  shall  be  stated,  together  with  the 
criteria, both favourable and unfavourable, for  evaluating 
the results. 
Each  investigator  shall  give  his  name,  address,  appoint-
ments,  university  qualifications  and  clinical  duties,  state 
where the  trial  was carried out and assemble  the follow-
ing  information  in  respect  of  each  patient  individually: 
I.  identification  of the patient (e.g.,  by  reference  to the 
number of his medical file); 
2.  criteria  determining  admission  of  the  patient to  the 
trials; 
3.  patient's age; 
4.  patient's sex; 
5.  diagnosis  and  indication  for  which  the  product  was 
administered  and  the  patient's  hisrory;  relevant 
particulars of any  previous illnesses shall be given; 
6.  dosage and method of admir.istration of the product; 
7.  frequency  of  administration  and  any  precautions 
taken at the time of administration; 
8.  duration  of treatment  and  of  the  subsequent  obser-
vation period; 
9.  details of medicinal  products administered previously 
or concomitantly, i.e.  at any  time  during the  period 
covered by  the investigation; 
10.  dietary regime, if  pertinent; 
11.  all  results of the clinical trials (including unfavourable 
or negative  results)  with  a  full  statement of clinical 
observations  and  results  of  clinical  investigations 
(such as X-rays, electroencephalograms, electrocardio-
grams,  laboratory .analyses,  physiological  tests  etc.), 
required  to  evaluate  the  application.  The techniques 
used  must  be  specified,  and  the .  significance  of any 
variations  in  the  results  explained  (for  example, 
variance  in method, variance  between individuals or 
the effects of treatment); 
12.  all  particulars  of  the  observed  side-effects,  whether 
harmful  or  not,  and  any  measures  taken  in  conse-
quence.  Relation  of  cause  and  effect  must  be 
investigated  with  the  same  care  normally  accorded 
to identifying 'herapeutic action; 
13.  an opinion concerning each individual case. 
-Omission  of  one  or  more  of  items  1  to  13  must  be 
explained. 
The information referred to above must be forwarded to 
the competent authorities. 
The competent authorities may waive this requirement in 
whole or in part if the documentation  is  very  extenaive 
or if there are other adequate reasons of the same order, 
subject, however, to there being no doubt as to the sound 
basis  of  the  summary  and  conclusions  referred  to  in 
point 2 below. 
The  person  responsible  for  plaGing  the  proprietary 
medicinal product on the market must make arrangements 
to  ensure  that the original  documents  which  formed  the 
basis  of  the  data  supplied,  including  the  codes  fot 
associating those documents with the patients in  question, 
arc  kept for at least  five  years  following  transmission  of 
the dossier to the competent authority. 
2.  Summary and conclusions 
1.  The clinical  observations  referred  to in  items  1  to  13 
of paragraph  1  above,  shall  be  summarized  in  a 
synopsis of the trials and their results, indicattng: 
(a)  the number and sex of patients treated; 
(b) the  selection  and  age-distribution  of  the  groups 
of  patients  being  investigated  and  the  control 
groups; 
(c)  the  number  of ·patients  withdrawn  prematurely 
from  the  trials  and  the  reasons  for  such  with· 
drawal; 
(d) where controlled trials were carried  out under the 
abnve conditions, whether the control group: 
- received no treatment, 
- received a placebo, 
- received  another  medicinal  product  of  known 
effect; 
(e)  the frequency of observed side-effects; 
(f)  details concerning patients who may be at increased 
risk,  e.g.  elderly  people,  children,  women  durina 
pregnancy or menstruation, or whose physiological 
or  pathological  condition  requires  special 
consideration; 
(g)  a  statistical  evaluation  of the  results  when  this it 
called  for  by  the  design  C1f  the  trials  and  the 
variable factors involved. 
2.  Finally the investigator shall, in the general conclusions 
on the experimental  evidence,  express  an  opinion on 
the safety of the product under normal conditions of 
use,  its  compatibility, its  therapeutic efficacy  and any 
useful information relating  to indications and contra· 
indications, dosage and average duration of ti-tatment 
as  well  as any  special  precautions to be taken during 
treatmCJ,lt and the dini'al symptolll$ of overdosage. 
C. GENERAL CONSIDERATIONS 
1.  The  clinician  ahall  always  indicate. his  observations 
on: 
(a)  any sips of habituation, addiction or difficulty in 
weaning patients from the medicinal product; - 28-
(b)  any  interactions  that  have  been  observed  with 
other  medicinal  products  administered 
concomitantly; 
(c)  the criteria determiniug exclusion of certain patients 
from  the trials. 
2.  Particulars concerning a new combination of medicinal 
substances must be  identical to those required  for  new 
medicinal  products  and  must  substantiate  the  safety 
and therapeutic efficacy of the combination. 
CHAPTER  III 
EXAMINATION OF APPLICATIONS FOR 
AUTHORIZATION TO PLACE A PROPRIETARY 
MEDICINAL PRODUCT ON THE MARKET 
In  examining  any  application  submitted  pursuant  to 
Article 4 of Directive 65/65/EEC, the competent authorities 
of Member States shall apply the following principles. 
1.  Evaluation  of  the  application  for  marketing  authori-
zation  shall  be  based  on  clinical  trials  or  clinical 
pharmacological  experiments  designed  to  determine 
the  therapeutic  efficacy  and  safety  of  the  product 
under normal  conditions of use,  having  regard  to the 
therapeutic  indications  for  use  in  human  beings. 
Therapeutic advantages must omweigh potential risks. 
'  Clinical  statements concerning the  therapeutic efficacy 
or  safety  of  a  proprietary  medicinal  product  under 
normal  conditions  of  use  which  are  not scientifically 
substantiated cannot be accepted as valid evidence. 
3.  Demonstration of pharmacodynamic effects  in  human 
beings  shall  not  in  itself  be  sufficient  to  justify 
conclusions  regarding  any  particular  potential  thera-
peutic effect. 
4.  The  value  of  data  on  the  therapeutic  efficacy  and 
safety of a proprietarY. medicinal  product under normal 
conditions  of  use  will  be  very  greatly  enhanced  if 
such  data  come  from  several  competent  investigators 
working independently. 
5.  When,  in  respect  of particular therapeutic  indications, 
the  applicant  can  show  that he  is  unable  tn  provide 
comprehensive data on  therapeutic efficacy  and safety 
under normal conditions of use, because: 
(a)  the  indications  for  which  the  product  in  question 
is  intended  are  encountered  so  rarely  that  the 
applicant cannot reasonably be expected to provide 
comprehensive evidence, or 
(b)  in  'the  present  state  of  scientific  knowledge 
comprehensive information cannot be provided, or 
(c)  it  would  be  contrary  to  generally  accepted  prin-
ciples of medical ethics to collect such information, 
marketing  authorization  may  be  granted  on  the 
following conditions: 
(a)  the  proprietary medicinal  product in  question  may 
be  supplied  on  medical  prescription  only  and  may 
in  certain  cases  be  administered  onl;y  under  strict 
medical supervision, possibly in a hospital; 
(b) the  package  leaflet  and  any  medical  information 
shall draw the attention of the medical  practitioner 
to the fact that the particulars available concerning 
the  proprietary  medicinal  product  in  question  is 
as  yet inadequate in certain specified respects. - 29-
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SECOND COUNCIL DIRECTIVE 
of 20 May 1975 
on the  approximation  of  provisions  laid  down  by  law,  regulation  or administrative 
action relating to proprietary medicinal products 
(75/319/EEC) 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having  regard  to  the  Treaty  establishing  the 
European  Economic  Community,  and  in  particular 
Article 100 thereof; 
Having regard to the proposal from the Commission; 
Having  regard  to  the  Opinion  of  the  European 
Parliament (1j; 
Having  regard  to the Opinion of the  Economic  and 
Social Committee (2); 
Whereas  the  approximation  begun  by  Council 
Directive  65/65/EEC (3)  of  26  January  1965  on the 
approximation  of  provisions  laid  down  by  law, 
regulation  or  administrative  action  relating  to 
proprietary  medicinal  products  should  be continued 
and  the  implementation  of the  principles  laid  down 
in that Directive should be ensured; 
Whereas  in  order  to  reduce  the  disparities  which 
remain,  rules  should be  laid  down on the control of 
proprietary  medicinal  products  and  the  duties 
incumbent  upon  the  Member  States'  competent 
authorities  should  be  specified  with  a  view  to 
ensuring compliance with legal requirements; 
Whereas, in  order to progress towards free movement 
of  proprietary  medicinal  products,  the  issue  of 
authorizations to place one and the same proprietary 
medicinal  product  on  the  market  in  two  or  more 
Member States should be facilitated; 
Whereas,  for  this  purpose,  a  Committee  for 
Proprietary  Medicinal  Products  should  be  set  up, 
consisting  of  representatives  of  the  Member  States 
and  of  the  Commission,  responsible  for  giving  an 
opinion  as  to  whether  a  particular  proprietary 
medicinal  product  complies  with  the  requirements 
set out in Directive 65165/EEC; 
(')  OJ No 96, 2. 6. 1965, p. 1677/65. 
(I)  OJ No 107, 19. 6. 1965, p. 1825/65. 
(')  OJ No 22, 9. 2. 1965, p. 369165. 
Whereas  this  Directive  represents  merely  one  step 
towards  achievement  of  the  objective  of  the  free 
movement  of  proprietary  medicinal  products; 
whereas,  therefore,  further  measures  with  a  view 
to  abolishing  any  remaining  barriers  to  the  free 
movement  of  proprietary  medicinal  products  will 
be  necessary  in  the light of experience. gained,  parti-
culariy in the abovementioned Committee; 
Whereas  in  order  to  facilitate  the  movement  of 
proprietary  medicinal  products  and  to  prevent  the 
controls carried out in one Member State from  being 
repeated  in  another,  minimum  requirements  should 
be  laid  down  for  manufacture  and  imports  coming 
from  third  countries  and  for  the  grar.t  of  the 
authorization relating thereto; 
Whereas  it  should  be  ensured  that,  in  the  Member 
States, the supervision and control of the manufacture 
of  proprietary  medicinal  products  is  carried  out by 
a  person  who  fulfils  minimum  conditions  of 
qualification; 
Whereas,  moreover,  the  provisions  of this  Directive 
and  of that of Directive  65/65/EEC  which  relate  to 
proprietary  medicinal products, although appropriate, 
are  inadequate  for  vaccines,  toxins  and  serums, 
proprietary  medicinal  products  based  on  human 
blood  or  blood  constituents,  proprietary  medicinal 
products  based  on  radio-active  isotopes  and 
homeopathic  proprietary  medicinal  products; 
whereas  the  application thereof should consequently. 
not be imposed at the present time in  respect of such 
proprietary medicinal products; 
Whereas  certain  rules  in  this  Directive  entail 
amendments  to  various  provisions  of  Directiv•: 
65/65/EEC, 
HAS ADOPTED THIS DIRECTIVE : 
CHAPTE.R.  I 
Application for authorization to place propriecay 
mediciDal products on the ~ 
Article  1 
Member  States  shall  take  all  appropriate  measures 
to  ensure  that the  documents  and particulars limd - 30-
in  points  7  and  8  of  Article  4,  second  paragraph, 
of  Directive  65/65/EEC  arc  drawn  up  by  experts 
with  the  necessary  technical  or  professional  qualifi-
cations  before  they  arc  submitted  to  the  competent 
authorities.  These  documents  and  particulars  shall 
he signed by  the experts. 
Article 2 
The duties of the experts according to their respective 
qualifications shall be: 
(a)  to  perform  tasks  falling  within  their  respective 
disciplines  (analysis,  pharmacology  and  similar 
experimental  sciences,  clinical  trials)  and  to 
describe  objectively  the  results  obtained  (qualita-
tively and quantitatively); 
(b)  to describe their observations in  accordance with 
Council  Directive  75/318/EEC (1)  of  20  May 
1975,  on  the  approximation  of  the  laws  of  the 
Member  States  relating  to  analytical,  pharmaco-
toxicological  and clinical  standards and protocols 
in  respect  of the  testing  of proprietary  medicinal 
products, and to state, in  particular: 
- in  the case of the analyst, whether the product 
is  consistent  with  the  declared  composition, 
giving  any  substantiation  of  the  control 
methods employed by the manufacturer; 
in  the  case  of  the  pharmacologist  or  the 
specialist  with  similar  experimental  com-
petence,  the  toxicity  of  the  product  and  the 
pharmacological properties observed; 
in  the  case  of  the  clinician,  whether  he  has 
been  able  to  ascertain  effects  on  persons 
treated  with  the  product  which  correspond 
to  the  particulars  given  by  the  applicant  in 
accordance  with  Article  4  of  Directive 
65/65/EEC,  whether  the  patient  tolerates  the 
product  well,  the  posology  the  clinician 
advises  and  any  contra-indications  and  side-
effects; 
(c)  where  applicable,  to state  the  grounds  for  using 
the published  rcfncnces mentioned in point 8  (a) 
and  (b)  of  Article  4,  second  paragraph,  of 
Directive 65/65/EEC under the conditions set  out 
in  Directive 75/318/EEC. 
Detailed  reports  by  the  experts  shall  form  p::lft  of 
the  particulars  accompanying  the  application  which 
the applicant submits to the competent authorities. 
(1)  See  page 1 of this Official Journal. 
Article  J 
In  the event of Article  2 of this  Directive  not being 
complied  with,  Article  5,  second  paragraph,  of 
Directive 65/6S;EEC shall apply. 
CHAPTER  II 
Examination  of  the  application  for authorization  to 
JPiacc proprietary medical products on the market 
Article  4 
In  order  to  examine  the  application  submitted  in 
accordance  with  Article  4  of  Directive  65 165/EEC, 
the competent authorities of the Member States: 
(a)  must verify  whether the  particulars  submitted  in 
support of the  application  comply  with  the  said 
Article  4  and  examine  whether  the  conditions 
for  issuing  an  authorization  to place  proprietary 
medicinal  products  on  the  market  (marketing 
authorization) arc complied with; 
(b)  may  submit  the  proprietary  medicinal  product 
for  testing by a State laboratory or by a laboratory 
designated  for  that  purpose  in  order  to  ensure 
that  the  control  methods  employed  by  the 
manufacturer  and  described  in  the  particulars 
accompanying the application in  accordance with 
point  7  of  Article  4,  second  paragraph,  of 
Directive 65/65/EEC are satisfactory; 
(c)  may,  where  appropriate,  require  the  applicant 
to  supplement  the  particulars  accompanying  the 
application  in  respect  of  the  items  listed  in  the 
second  paragraph  of  Article  4  of  Directive 
65/65/EEC.  Where the competent authorities avail 
themselves  of  this  option,  the  time  limits  laid 
down  in  Article  7  of  the  said  Directive  shall 
be  suspended  until  such  time  as  the  supplemen-
tary  information  required  has  been  provided. 
Likewise,  these time limits shall be suspended for 
the  time  allowed  the  applicant,  where  appro-
priate, for giving oral or written explanation. 
Article  5 
Member  States  shall  take  all  appropriate  measures 
to ensure that: 
(a)  the  competent  authorities  verify  that  manufac-
turers  and  importers  of  products  coming  from 
third countries are able to carry out manufacture 
in  compliance  with  the  particulars  supplied 
pursuant  to  point  4  of  Article  4,  second 
paragraph,  of  Directive  65/65/EEC  and/or  to 
carry  out  controls  according  to  the  methods 
described  in  the  particulars  accompanying  the 
application in  accordance with point 7  of Article 
4, second paragraph, of that Directive; - 31-
{b)  the  competent  au.thorities  may  allow  manufac-
turers  and  impotters  of  products  coming  from 
third  countries,  in  exceptional  and  justifiable 
cases,  to have  cettain stages  of manufacture and/ 
or certain of the controls referred to in  {a)  carried 
our  by  third  patties;  in  such  cases,  the  verifi-
catirms  by  the  competent  authorities  shall  also 
be made in the establishment designated. 
Article  6 
Where  a  leaflet  is  enclosed  with  the  packaging  of 
a proprietary medicinal  product Member States shall 
take all  appropriate measures ro ensure that it applies 
to the product in question only. 
All  the  information  given  in  the  leaflet  must  be  in 
accordance  with  the  patticulars  and  documents 
supplied pursuant to Article 4 of Directive 65/65/F.F.C 
and must be approved by the competent authorities. 
The  leaflet  must  include  at  least  the  following 
information: 
{a)  name  and  domicile  or  corporate  name  and 
domicile  or  registered  place  of  business  of  the 
person  responsible  for  marketing  the  product 
and, where applicable, of the manufacturer; 
{b) name  and qualitative and quantitative patticulars 
of rhe product in terms of irs active ingredients. 
The  international  non-proprietary  names 
recommended by  the World Health Organization 
should be used where such names exist; 
{c)  in  the  absence  of  a  decision  to the  contrary  by 
the co!Tlpetent authorities: 
- therapeutic indications, 
- contra-indications,  side  effects  and  special 
precautions for use. 
Information  and  decisions  under  the  first  and 
second indents shall take into accouQt the results 
of  the  clinical  trials  and  pharmacological  tests 
provided  for  in  point  8  of  Anicle  4,  second 
paragraph,  of  Directive  65/65/EF.C  and  in  the 
case  of  the  information  referred  lO  under  the 
second  indent,  of  experience  acquired  in  use 
after marketing; 
(d~ directions  for  use  of  the  product  (method  of 
administration,  duration  of  treatment  if  this 
should be limited, normal doaqe); 
(e)  special storage precautions, where applicable. 
Other  information  shall  be  clearly  separate  from 
that referred to above.  . 
Member St;<te  may  require that a leaflet be  included 
with the packaging. 
Article  7 
Notwithstanding  the  provisions  of  Chapter  IV  and 
of Atticle 21  of Directive 65/65/F.F.C,  Member States 
may  require  that the  proprietary  medicinal  product 
shall  be  labelled  so  as  to  indicate  on  the  container 
and/or outer packaging and/or on the package leaflet 
other  requirements  ess'enrial  to  safety  or  for  the 
protection  of public health,  including any  panicular 
precautions  to  be  taken  in  using  the  product  and 
any  other  warnings  based  on  the  results  of  the 
clinical  trials  and  ph:umacological  tests  mentioned 
in  point  8  of  Atticle  4,  second  paragraph,  of 
Directive 65/65/F.F.C,  or resulting from  experience in 
the  course  of  use  of  the  proprietary  medicinal 
product after marketing. 
CHAPTER  Ill 
Committee for Proprietary Medicinal Products 
Article  8 
1.  In  order to facilitate  the adoption  of a common 
position  by  the  Member  States  regarding  marltetma 
authorizations,  a  Committee  for  Proprietary 
Medicinal  Products,  hereinafter  referred  to  as ·'the 
Committee',  is  hereby  set up.  The Committee. ahall 
consist  of representatives  of the Member  Sta11ea  and 
of the Commission. 
2.  The  responsibility  of the Committee shall  be  to 
examine,  in  accordance  with  Articles  9  to  14,  the 
questions referred to it by a Member State concerning 
the  application  of Atticles  5,  11  or 20  oi  Directive 
65/65/F.F.C. 
3.  The Committee shall  draw up its  own llules  of 
Procedure. 
Article  9 
1.  The Member State which has  issued a marketing 
authorization  for  a  proprietary  medicinal  product 
shall forward  to the Committee a dossier  containing 
a  copy  of  the  authorization  together  with  the 
patticulars  and  documents  specified  in  Article  4, - 32-
second  paragraph,  of  Directive  65/65/EEC,  if  the 
person  responsible  for  marketing  has  requested  the 
forwarding to at least five other Member States. 
2.  The  Committee  shall  forthwith  forward  the 
dossier  to  the  competent  authorities  of  the  Member 
St:~tes so specified. 
3.  Such  forwarding shall be  deemed to be equivalent 
to  submitting  an  application  for  marketing 
authorization,  within  the  meaning  of  Article  4  of 
Directive 65/65/EEC, to the said authorities. 
Article  10 
1.  If,  within  a  period  of  120  days  after  the  date of 
the  forwarding  referred  to  in  Article  9  (2),  no 
ob;ection  is  notified  to  the  Committee  by  the 
competent authorities of the Member States specified, 
the  Committee  shall  formally  record  the  fact  and 
forthwith inform the Member States concerned. 
2.  Where a Member State considers that it  is  unable 
to  authorize  the  marketing  of  the  proprietary 
medicinal  product,  it  shall  forward  its  reasoned 
objection, within  the  said  period of 120 days,  on the 
basis of Article 5 of Directive 65/6.5/EEC. 
Article  11 
1.  In  the  cases  referred  to  in  Article  10  (2),  the 
Committee  shall  consider  the  matter  and  give  a 
reasoned  opinion  within  not  more  than  60  days 
from  the  expiry  of  the  time  limit  laid  down  in 
Article 10. 
2.  The  opinion  of  the  Committee  shall  deal  with 
the  compliance  of the  proprietary. medicinal  product 
with  the  conditions set  out in  Article  5  of Directive 
65/65/EEC. 
The  Committee  shall  forthwith  inform  the  Member 
States  concerned  of  its  opinion  or,  in  the  event  of 
a divergence, of the opinions of its members. 
3.  The  Member  States  concerned  shall  reach  a 
decision  on  the  application  for  marketing 
authorization  not  more  than  30  days  after  the  date 
on  which  the  information provided for in  Article 10 
(1)  or paragraph 2 of this  Article is given. They shall 
forthwith inform the Committee of their decision. 
Article  12 
1.  If several  applications  submitted  in  accordance 
with  Article  4  of  Directive  65/65/EEC  have  been 
made  for  marketing  authorization  for  a  particular 
proprietary  medicinal  product,  and  one  or  more 
Member States  have  granted  an  authorization  while 
one or more of the other Member States have refused· 
it,  one  of  the  Member  States  concerned  may  bring 
the matter before the Committee. 
The same  shall  apply  where  one  or  more  Member 
States  have  suspended·  or  revoked  the  marketing 
authorization  while  one  or  more  other  Member 
States have not done so. 
2.  The  Committee  shall  consider  the  matter  and 
give a reasoned opinion within 120 days at the most. 
3.  The  opinion  of  the  Committee  shall  only  deal 
with the grounds on which authorization was refused, 
suspended or revoked. 
The  Committee  shall  forthwith  inform  the  Member 
States  concerned  of its  opinion  or,  in  the  event  of 
a divergence, of the opinions of its members. 
4.  The  Member  States  concerned  shall  give  notice 
within  30  days  of  the  action  they  intend  to  take 
following the Committee's opinion. 
Article  13 
The  Committee  may  set  a  ~ime  limit ·for  a  fresh 
examination  on  the  basis  of  particulars  relating  to 
the  conditions  laid  down  in  Articles  5,  11  or  20 
of  Directive  65/65/EEC  obtained  in  the  meantime 
by  the  Member States,  in  particular by  those  which 
have authorized the proprietary medicinal product. 
Article  14 
The  competent  authorities  of  Member  States  may, 
in  specific cases where the interests of the Community 
are  involved,  refer  the  matter  to  the  Committee 
before  reaching  a  decision  on  an  application  for 
a  marketing  authorization,  its  suspension  or 
revocation. 
Article  15 
1.  The  Commission  shall  report  to  the  Council 
annually  on  the  operation  of  the  procedure  laid 
down  in  this  Chapter  and  its  effects  on  the 
development  of  intra-Community  trade.  It  shall 
report  for  the  first  time  two  years  after  the  entry 
into force of this Directive. 
2.  In  the light of experience the Commission shall, 
not later  than four  years  after the entry into  force 
of this  Directive,  submit  to the  Council  a  proposal 
containing  appropriate  measures  leading  towards 
the  abolition  of any  remaining  barriers  to  the .ftee 
mclvement  of  proprietary  medicinal  products.  The 
Council  shall  take  a  decision  on  the  Commission 
proposal no later than one year after its submission. - 33-
CHAPTER  IV 
Manufacture and imports coming from third 
countries 
Article  16 
1.  Member  States  shall  take  all  appropriate 
measures  to  ensure  that  the  manufacture  of  the 
proprietary  medicinal  products  is  subject  to  the 
holding of an authorization. 
2.  The authorization refened to in  paragraph 1 shall 
be  required  for  both  total  and  partial  manufacture, 
and  for  the  various  processe~  of  dividing  up, 
packaging or presentation. 
However,  such  authorization  shall  not  be  required 
for  prep2ration,  dividing  up,  changes  in  packaging 
or  presentation  where  these  processes  are  carried 
out,  solely  for  retail  supply,  by  pharmacists  in 
dispensing  pharmacies  or  by  persons  legally 
authorized  in  the  Member  States  to  carry  out such 
processes. 
3.  Authorization  referred  to  in  paragraph  1  shall 
also  be  required  for  imports  coming  from  third 
countries  into  a  Member  State;  this  Chapter  and 
Article  29  shall  have  corresponding  application  to 
such imports as they have to manufacture. 
Article  17 
In  order  to  obtain  the  authorization  referred  to  in 
Article  16,  the  applicant  must  meet  at  least  the 
following requirements: 
(a)  specify  the  proprietary  medicinal  products  and 
pharmaceutical  forms  which  are  to  be 
manufactured  or  imported  and  also  the  place 
where  they  are  to  be  manufactured  and/or 
controlled; 
(b)  have  at  his  disposal,  for  the  manufacture  or 
import  of  the  above,  suitable  and  sufficient 
premises,  technical  equipment  and  control 
facilities  complying  with  the  legal  requirements 
which  the  Member  State  concerned  lays  down 
as  regards  both  manufa~ture  and  control  and 
the  storage  of  products,  in  accordance  with 
Article 5 (a). 
(c)  have  at his  disposal  the  services  of at  least  one 
qualified person within the meaning o{ Article 21. 
The  applicant  must  provide  particulars  in  support 
of the above in his application. 
Article  18 
1.  The  competent  authority  of  the  Member  State 
shall  issue  the authorization referred to in Article 16 
only  after  having  made sure  of the accuracy of the 
particulars supplied pursuant to Article 17, by means 
of an inquiry carried out by its agents. 
2.  In  order to ensure that the  requirements  referred 
to  in  Article  17  are  complied  with,  authorization 
may  be  made  conditional  on  the  carrying  out  of 
certain obligations imposed either when authorization 
is granted or at a later date. 
3.  The  authorization  shall  apply  only  to  the 
premises  specified  in  the  application  and  to  the 
proprietary  medicinal  products  and  pharmaceutical 
forms specified in that same application. 
Article  19 
The holder of an  authorization referred to in Article 
16 shall at least be obliged: 
(a)  to have at his  disposal  the services  of staff who 
comply with the legal requirements existing in the 
Member  State  concerned  both  as  regards 
manufacture and controls; 
(b) to dispose of the authorized proprietary medicinal 
products  only  in  accordance  with  the  legislation 
of the Member States concerned; 
(c)  to  give  prior  notice  to  the  competent  authority 
of  any  changes  he  may  wish  to  make  to  any 
of the particulars supplied pursuant to Article 17; 
the  competent  authority  shall  in  any  event  be 
immediately  informed  if  the  qualified  person 
referred to in Article 21  is replaced unexpectedly; 
(d) to  allow  the  agents  of  the  competent  authority 
of  the  Member  State  concerned  access  to  his 
premises at any time; 
(e)  tQ  enable  the  qualified  person  referred  to  in 
Article  21  to  carr)'  out  his  duties,  for  example 
by  placing  at  his  disposal  all  the  necessary 
facilities. 
Article 20 
1.  The  Member  States  shall  take  all  approt>riate 
measures  to  ensure  that  the  time  taken  for  the 
procedure  for  granting  the  authorization  referred 
to  in  Article  16  does  not exceed  90  days  from  the 
day  on  which  the  competent  authority  receives  the 
application. 
2.  If the holder of the authorization requests a change 
in  any  of  the  particulars  referred  to  in  Article  17 
(a)  :tnd (b), the time taken for the procedure relating 
to  this  request  shall  not  exceed  30  days.  In 
exceptional cases this period of rime may be extended 
to 90 days. 
3.  Member  States  may  require  from  the  applicant 
further  information  concerning  the  particulars 
supplied  pursuant to  Article  17 and concerning the 
qualified  person  referred  to  in  Article  21;  where 
the  competent  authority  concerned  exercises  this 
i:ight,  application  of the  time  limits  referred  to  in 
paragraphs  1  and  2  shall  be  suspended  until  the 
additional data required have been supplied. - 34-
Article  21 
1.  Member States shall take all appropriate measures 
to ensure that the holder of •he  authorization referred 
to  in  Article  16  has  permanently  and  continuously 
at his  disposal  the  services  of at  least  one  qualified 
person, in  accordance with  the  conditions laid  down 
in  Article  23,  responsible  in  particular  for  carrying 
out the duties specified in Article 22. 
2.  If heo personally  fulfils  the  conditions  laid  down 
in  Article  23,  the  holder  of  the  authorization  may 
himself  assume  the  responsibility  referred  to  in 
paragraph 1. 
Article  22 
1.  Member States shall take all  appropriate measures 
to  ensure  that  the  qualified  person  referred  to  in 
Article 21, without prejudice to his  relationship with 
the holder of the authorization referred  to  in  Article 
16,  is  responsible,  in  the  context of the  procedures 
referred to in Article 25, for securing: 
(a)  in  the  case  of  proprietary  medicinal  products 
manufactured  within  the  Member  States 
concerned  that  each  batch  of  proprietary 
medicinal  products  has  been  manufactured  and 
checked  in  compliance  with  the  laws  in  force 
in  that  Member  State  and  in  accordance  with 
the requirements of the marketing authorization; 
(b) in  the  case  of  proprietary  medicinal  products 
coming from  third countries, that each production 
batch  has  undergone  in  the  importing  country 
a  full  qualitative  analysis,  a  quantitative  analysis 
of at least  all  the  active  constituents  and all  the 
other  tests  or  checks  necessary  to  ensure  the 
quality  of  proprietary  medicinal  products  in 
accordance  with  the  requirements  of  the 
marketing authorization. 
The  batches of products which have undergone such 
controls in  a Member State shall  be exempt from  the 
above  controls  if  they  arc  imported  into  another 
Member  State,  accompanied  by  the  control  reports 
signed by the qualified person. 
A  Member  State  may  relieve  the  qualified  person 
of  responsibility  for  the  controls  prescribed  under 
(b)  for  imported  proprietary  medicinal  products 
which  are  to  remain  in  that  Member  State,  if 
appropriate  arrangements  have  been  made  with  the 
exporting country to ensure that those controls have 
been  carried  out  in  the  exporting  coun'try.  Where 
these  products  are  imported  in  the  packaging  in 
which  they  are  to be  sold by  retail,  Member States 
may allow exceptions to the requirements laid down 
in Article 17. 
2.  In all cases and particularly where the proprietary 
medicinal  products are released for sale the qualified 
pt:r~on  11111't  Lntify  111  a  register  or  L'lJIIIvalcnt 
document  provided  for  that  purpose  that  each 
production  batch  sati~fics  the  provisions  of  this 
Article;  the  said  register  or  equivalent  domment 
mus•  he  kept  up  to  d;Jtc  as  operations  arc  carried 
out  and  mmt  remain  .It  the  disposal  of  the  agents 
of  the  competent  authority  for  the  period  spcLcilficd 
in  the  provi,ions  of  the  Member  State  com:crned 
and in  any event for at least five  years. 
Artirle  23 
Member '>tares  shall  cmure that the qualified  pn:>on 
referred  to in  Article 21  fulfils the fo.llowing m111im!!m 
conditions of qualification: 
(a)  Possession  of  a  diploma,  certificate  or  other 
evidence  of  formal  qualifications  awarded  on 
completion  of  a  university  course  of  study,  or 
a course recogni1.ed  as  equivalent by  the  M•·mher 
State  concerned,  extending  over  a  period  oi  at 
least  four  years  nf  theoretical  and  practical  study 
in  one  nf  the  following  scientific  disciplines: 
pharmacy,  medicine,  veterinary  meJicine, 
chemistry,  pharmaceutical  chemistry  and 
technology, biology. However: 
the minimum duration of the university cnttrse 
may  be  three  and  a  half  years  where  the 
course  is  iollowed  by  a  period of theorct ical 
and practical training of a minimum duration 
of  one  year  and  including  a  training  period 
of  at  least  six  months  in  a  pharmacy  open 
to the public, corroborated by an examination 
at university level; 
where  two  university  courses  or two  courses 
recognized  by  the State  as  equivalent cP-e'\ist 
in  a  Mcmhcr  State  and  where  one  of  th•·sc 
extends  over  four  years  and  the  other  over 
three  years,  the  three-year  course  lc:1ding  tn 
a  diploma,  certificate  or  other  evidence  of 
formal  qualifications  awarded  on  completion 
of  a  university  course  or  its  rccognind 
equivalent  shall  be  considered  to  fulfil  the 
condition  of duration  referred  to in  (a)  in  so 
far  as  the  diplomas,  certificates  or  or her 
evidence  of formal  qualifications  awarclrd  on 
completion  of  both  courses  are  rccogni1.ed 
as equivalent by the State in question. 
The course shall include theoretical and  practical 
study  bearing  upon  at  least  the  following  basic 
subjects: 
Applied physics 
General and inorganic chemistry 
Organic chemistry 
Analytical chemistry 
Pharmaceutical  chemistry,  including  analysis  of 
medicinal products 
General and applied biochemistry (medical) 
Physiology - 35-
Microbiology 
Pharmacology 
Pharmaceutical technology 
Toxicol:>gy 
Pharmacognosy  (medical  aspects)  (study  of  the 
composition  and  effects  of  the  active  principles 
of natural substances of plant and animal origin). 
Studies  in  these  subjects  should  be  so  balanced 
as  to  enable  the  person  concerned  to  fulfil  the 
obligations specified in Article 22. 
In  so  far as  certain diplomas, c.ertificates or other 
evidence  of  formal  qualifications  mentioned  in 
(a)  do not fulfil  the  cci~eria laid down above,  the 
competent  authority  of  the  Member  State  shall 
ensure  that  the  person  concerned  provides 
evidence  of  adequate  knowledge  of the  subjects 
involved. 
(b)  Practical  experience  for  at  least  two  years,  in 
one  or  more  undertakings  which  are  authorized 
to  manufacture  proprietary  medicinal  products, 
in  the activities of qualitative analysis of medicinal 
products,  of  quantitative  analysis  of  active 
su hstances and of the testing and checking neces-
sary to ensure the quality of proprietary medicinal 
products. 
The duration of practical experience may be reduced 
hy  one  year  where  a  university  course  lasts  for  at 
least five  years  and  by  a year  and a  half where  the 
course lasts for at least six years. 
Article  24 
1.  A  person  engaging in  the  activities  of the  person 
referred  to  in  Article  21  in  a  Member State  at  the 
time  when  this  Directive  is  brought  into  force  in 
that State but without complying with the provisions 
of Article  23  shall  be  eligible  to  continue to engage 
in those activities in the State concerned. 
2.  The  holder  of  a  diploma,  certificate  or  other 
evidence  of  formal  qualifications  awarded  on 
completion  of  a  university  course  - or  a  course 
recognized  as  equivalent  by  the  Member  State 
concerned  - in  a  scientific  discipline  allowing  him 
to engage in the activities of the person referred to in 
Article  21  in  accordance  with  the  laws  of  that 
State  may  - if  he  began  his  course  prior  to  the 
notification  of  this  Directive  - be  considered  as 
qualified to carry out in  that State the duties of the 
person referred to in Article 21  provided that he has 
previously  engased  in  the  followins  activities  for 
at least  two years  before  the end  of the tenth year 
following  notification  of  this  Directive  in  one  or 
more undertakings authorized pursuant to Article 16: 
production  supervision  and/or  qualitative  analyaia, 
quantitative  analysis  of  active  subataneea,  and  the 
necessary  teiting  and  checkins  under  the  direct 
authority of the  person  referred  to in  Article 21  to 
ensure  the  quality  of  the  proprietary  medicinal 
products. 
If the  person  concerned  has  acquired  the  practical 
experience referred to in the first subparasraph more 
than  10  years  prior  to  the  notification  of  this 
Directive,  a  furt~er one  year's  practical  experience 
in  accordance with the conditions referred to in  the 
first  subparagraph will  be  required  to be completed 
immediately before he engages in such activities. 
3.  A  person  who,  at the  time  when  this  Directive 
is  brought  intp  force,  is  engaged  in  direct 
collaboration with a person referred to in Article 21 
in  production  superv1s1on  act1v1t1es  and/  or  in 
qualitative  and  quantitative  analysis  of  active 
substances  and  the  testing  and  checking  necessary 
to  ensure  the  quality  of  proprietary  medicinal 
products  may,  for  a  period  of  five  years  after  this 
Directive has been  brought into force,  be considered 
as  qualified  to  take  up  in  that  State  the  duties  of 
the  person  referred  to  in  Article  21  provided  that 
that  Member  State  ensures  that  the  person  shows 
evidence  of  adequate  theoretical  and  practical 
knowledge  and  has  engaged  in  the  activities 
mentioned for at least five years. 
Article 25 
Member  States  $hall  ensure  that  the  duties  of 
qualified  persons  referred  to  in  Article  21  are 
fulfilled,  either  by  means  of  appropriate  adminis-
trative  measures  or by  making such  persons  subject 
to a professional code of conduct. 
Member  States  may  provide  for  the  temporary 
suspension of such a person upon the commencement 
of  administrative  or  disciplinary  procedures  against 
him for failure to fulfil his obligations. 
CHAPTER  V 
Supervision and sanctions 
Article 26 
The  competent  authority  of  the  Member  State 
concerned shall ensure by  means of inspections that 
the  leaal  requirements  relating  to  proprietary 
medicinal products are complied with. 
Such  inapections  shall  be  carried  out  by  officials 
repruentint the  competent  authority  whO  matt be 
empowered to: 
(a) inapect  manufacturina  or  commerc:ial  atablllh-
mentl  and  any  laboratories  iiitlattN  by  the 
holder of the authorization referred  to in Anide - 36-
16  with  the task of c1rrving out checks pursuant 
to Article 5 (b); 
ih)  take samples; 
',) examine  any  docunH'nt'  rd.ning  to  the  object 
of  the  inspection,  suhi<Tt  to  the  provisions  in 
force  in  the  Memhcr  States  at  the  time  of 
notification  of  this  Directive  and  which  place 
restrictions  on  these  power'  with  regard  to  the 
descriptions of the method of preparation. 
Artidc 27 
Member  States  shall  take  all  appropriate  measures 
to ensure  that the  person  responsible  for  marketing 
a  proprietary  medicinal  product  and,  where  appro-
priate, the holder of tlw  amhorization  referred to  in 
Article  16,  furnish  proof of  the controls carried  out 
on  the  finished  produ<t  and/or  the  ingredients  and 
of  the  controls carried  out  at  an  intermediate  stage 
of  the  manufacturing  process,  in  accordance  with 
the  methods  laid  down  for  the  purposes  of  the 
markrring authorization. 
Article  28 
I.  Notwithstanding  the  mcasmes  provided  for  in 
Article  II  of  Directive  6 S/liS/EEC  Memher  States 
'hall  take  all  apptopriarc  measures  to  ensure  that 
the  supply  of  the  proprietary  medicinal  product 
~hall  he  prohihited  and  tht•  proprietary  medicinal 
pro,luct withdrawn from  the market if: 
a)  the  proprietary  medicinal  product  proves  to  be 
harmful under normal conditions of usc; 
h)  it  is  lacking in  therapeutic efficacy; 
1()  its  qualitative  and  quantitative·  composition  ts 
not a' declared; 
(ci)  the  e<ontrols  on  the  finished  product  and/or  on 
the  ingredients  and  1  he  controls  at  an  inter-
mccliate  stage  of the  manufacturing process have 
not  been  ell  rred  om  or  if  some  other 
requirement  or  obligation  relating  to  the  grant 
of the authom.ation  referred  to in  Article  16  has 
not heen fulfilled. 
2.  The  competent  authority  may  limit  the 
prohibition  to supply the product, or its  withdrawal 
from  the  market,  to -those  batches  which  are  the 
'uhject of dispute. 
Article  29 
I:  The competent authority of a  Member State shall 
~u~pcnd or  revoke  the  authorization  referred  to  in 
Article  16  for  a  category  of  preparations  or  all 
preparations where any one of the requirements laid 
down in Article 17  is no longer met. 
2.  In  addition to the measures specified in  Article 28; 
the  compt·tcnt  authority  of  a  Member  State  may 
suspend  manufacture  or  imports  of  proprietary 
mcdicin.1l  products  coming  from  third  countries,  or 
suspend  or  revoke  the  authorization  referred  to  in 
Art ide  I 6  for  a  category  of  preparations  or  all 
prt·parations  where  Articles  18,  19,  22  and  27  arc 
not complied with. 
CHAPTER  VI 
Miscellaneous provisions 
Article  30 
Member  States  shall  talce  all  appropnate  measures 
to  ensure  that  the  competent  authorities  coiKcrned 
communicate  to  each  other  such  information  as  is 
appropriate  to  guarantee  that  the  requirements  for 
the  authorizations  referred  to  in  Artide  16  or 
marketing authorizations are fulfilled. 
Article  31 
All  dcci~ions taken  pursuant to  Articles  JR,  28  <llld 
29  and  all  negative  decisions  taken  pursuant  to 
Articles  S  (b)  and  11  (3)  shall  state  in  detail  the 
reasons  on  which  they  are  hased.  Such  deCisions 
shall  he  notified  to  the  party  concerned,  who  shall 
at  the  same  time  be  informed  of  the  remedies 
available  to  him  under  the  laws  in  force  and  of 
the time limit allowed for applying for such remedies. 
Article  32 
No  dcciqon  concerning  suspension  of  manufacture 
or of importation of proprietary  medicinal  products 
coming  from  third  countries,  prohibition  of  supply 
or  withdrawal  from  the  market  of  a  proprietary 
'medicinal  product  may  he  taken  except  on  the 
ground set out in Articles 28 and 29. 
Article  33 
Each  Member  State  shall  take  all  the  appropriate 
measures  to  ensure  that  decisions  authorizing 
marketing,  refusing  or  revoking  a  marketing 
authorization,  cancelling  a  decision  refusing  or 
revoking  a  marketing  authorization,  prohibiting 
supply, or withdrawing a  product from  the market, 
together  with  the  reasons  on  which  such  decisions 
are  based,  are  brought  to  the  attention  of  the 
Committee forthwith. - 37-
Article  34 
This  Directive  shall  apply  only  to  proprietary 
medicinal products for human use. 
Chapters  II  to  V  of  Directive  65/65/EEC  and  this 
Directive  shall  not  apply  to  proprietary medicinal 
products  consisting  of  vaccines,  toxins  or  serums, 
to  proprietary  medicinal  products  based  on  human 
hlood  or  blood  constituents  or  radioactive  isotopes, 
or  to  homeopathic  proprietary  medicinal  products. 
A  list,  for  information  purposes,  of  these  vaccines, 
toxin' and serums is given in the Annex. 
Article  3S 
The  following  shall  he  substituted  tor  point  7  of 
Arrick 4,  second paragraph, of Directive 65/65/EEC: 
'Description  of  the  control methods employed hy 
the  manufacturer  (qualitative  and  quantitative 
analysis  of  the  constituents  and  of  the  finished 
produd,  special  tests,  e.g.  sterility  tests,  tests 
for  the  presence  of  pyrogenic  substances,  the 
presence  of  heavy  metals,  stability  tests, 
biological  and  toxicity  tests,  controls carried  out 
at  an  intermediate  stage  of  the  manufacturing 
process).' 
Article  36 
The  following  shall  be  substituted  for  Article  11, 
second paragraph, of Directive 65/65/EEC: 
'An  authorization  shall  also  be  suspended  or 
revoked  where  the  particulars  supporting  the 
application  as  provided for in  Article 4 are found 
to  he  incorrect,  or  when  the  controls  referred 
to  in  Article  8  of  this  Directive  or in  Article  27 
of  the  Se:ond  Council  Dire.:tive  75/319/EEC (1) 
nf  20  May  1975  on  the  approximation  of 
provisions  laid  down  by  law,  regulation  or 
administra<ive  action  relating  to  proprietary 
medicinal products have not been carried out.' 
The following footnote shall be added: 
'(1)  OJ No L 147, 9.  6. 75, p.  13.' 
Article  37 
The  following  shall  be  substituted  for  Article  24 
of Directive 65/65/EEC: 
'Within the time  limits  and under the conditions 
laid  down  in  Article  39  (2)  and  (3)  of  second 
Directive 75/319/EEC, the rules laid down in this 
Directive  shall  be  applied  progressively  to 
proprietary  medicinal  products  covered  by  an 
authorization  to  place  on  the  market  by  virtue 
of previous provisions'. 
CHAPTER  VII 
Implementing provisions and transitional 
measures 
Article  38 
Member  States  shall  bring  into  force  the  laws, 
regulations  and  administrative  provisions  needed  in 
order to comply with this Directive within 18  months 
of  its  notification  and  shall  forthwith  inform  the 
Commission thereof. 
Member States shall communicate to the Commission 
the  text  of  the  main  prov1s1ons  of  national  law 
which  they  adopt  in  the  field  covered  by  this 
Directive. 
Article  39 
1.  As  regards  the  authorizations  referred  to  in 
Article  16  issued  before  the expiry  of the time  limit 
laid  down  in  Article  38,  Member  States  may.  grant 
an additional period of one year to the undertakings 
concerned  to  enable  them  to  comply  with  the 
provisions of Chapter IV. 
2.  Within  15  years  of  the  notification  referred  to 
in  Article  38,  the  other  provisions  of  this  Directive 
shall be applied progressively to proprietary medicinal 
products placed  on the market by  virtue of previous 
provisions. 
3.  Member  States  shall  notify  the  Commission, 
within  three years  following  the  notification  of this 
Directive,  of  the  number  of  proprietary  medicinal 
products  covered  by  paragraph  2,  and,  each 
subsequent  year,  of  the  number  of  these  products 
for  which  a  marketing  authorization  referred  fO  in 
Article  3  of Directive  65/65/EEC,  has  not yet  been 
issued. 
Article  40 
This Directive is addressed to the Member States. 
Done at Brussels, 20 May 1975. 
For the Council 
The President 
R.  RYAN - 38-
ANNF.X 
The expression 'vaccines, toxins or serums' used in  Article 34  shall cover in  particular: 
- agents  used  to  produce  active  immunity 
(such  as  cholera vaccine, BCG, polio vaccine, smallpox vaccine); 
- agents  used  to  diagnose  the  state  of immunity 
including in particular tuberculin and tuberculin PPD, toxins for the Schick  and Dick Test,, 
brucellin; 
- agents  used  to  produce  passive  immunity 
(such  as  diphtheria antitoxin, anti-smallpox globulin, antilymphocytic globulin). - 39-
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COUNCIL DIRECTIVE 
of 2  May 1978 
amending Second Directive 75/319/EEC on the approximation of provisions laid 
down by law, regulation or administrative action relating to proprietary medi-
cinal products 
(78/420/EEC) 
THE COUNCIL OF THE EUROPEAN 
COMMUNITIES, 
Having regard to  the Treaty establishing the European 
Economic  Community, and  in  particular Article  100 
thereof, 
Having regard  to  the  proposal  from  the  Commission, 
Having regard  to  the opinion of the European  Parlia-
ment (1), 
Having  regard  to  the  opinion  of  the  Economic  and 
Social  Committee (2), 
Whereas Second Council Directive 75/319/EEC of  20 
May  197 5  on  the  approximation  of  provisions  laid 
down  by  law,  regulation  or  administrative  action 
relating  to  proprietary medicinal  products (3)  set up a 
Committee  for  Proprietary  Medicinal  Products,  here-
inafter referred to  as 'the Committee', and entrusted it 
with the task of giving opinions on whether particular 
proprietary  medicinal  products  comply  with  the 
requirements  of  Council  Directive  65/65/EEC  of  26 
January 1965 on the approximation of provisions laid 
down  by  law,  regulation  or  administrative  action 
relating  to  proprietary  medicinal  products (4)  ; 
Whereas  Articles  9  and  10  of  Directive  75/319/EEC 
provide that, where the Community procedure is to be 
applied,  the  Member  State  which  has  issued  a 
marketing authorization shall  forward  a dossier to  the 
Committee which  shall  forthwith  forward  the  dossier 
to  the  competent  authorities  of  the  Member  States 
specified by the person responsible for marketing ; 
Whereas experience has shown that the provision that 
the dossiers shall  pass  through the Committee instead 
of being sent directly to the Member States concerned 
results  in  administrative  problems  in  the  forwarding 
of  voluminous  documentation  and  in  delays  in  the 
work  of  the  Committee ; 
Whereas,  in  order  to  solve  these  problems  and  to 
reduce the delays, it is necessary to amend these provi-
sions  to  enable  the  Member  State  which  initially 
issued  the marketing authorization to send the dossier 
directly to  the Member States concerned as  well  as  to 
the  Committee, 
(I) OJ No  C  266,  7.  II. 1977,  p.  45. 
(2)  OJ No  C  18,  23.  I.  1978,  p.  11. 
(3)  OJ No  L 147,  9.  6.  1975,  p.  13. 
(4)  OJ No  22,  9.  2.  1965,  p.  369/65. 
HAS  ADOPTED THIS DIRECTIVE: 
Article 1 
The  following  shall  be  substituted  for  Article  9  of 
Directive  75/319/EEC: 
'Article  9 
1.  The  Member  State  which  has  issued  a 
marketing  authorization  for  a  proprietary  medi-
cinal  product  shall,  if the  person  responsible  for 
marketing has  requested forwarding  to at least five 
other Member States, forward  a dossier containing 
a copy of this request and a copy of the authoriza-
tion  together with  the  particulars  and  documents 
listed  in  the  second  pa11'~ph of  Article  4  of 
Directive 65/65/EEC to the Committee and to the 
competent authorities of the Member States speci-
fied. 
2.  Such  forwarding shall be  deemed to be equi-
valent  to  the  submission  of  an  application  for 
marketing  authorization,  within  the  meaning  of 
Article  4  of  Directive  65/65/EEC,  to  the  said 
authorities. 
3.  The  Committee  shall  without  delay  inform 
the Member States concerned that the dossier  has 
been  received  by  the  Committee.' 
Article 2 
In  Article  10  (1)  of  Directive  75/319/EEC  the words 
'transmission of  the information referred  to  in Article 
9 (3)' shall be substituted for 'forwarding referred to  in 
Article  9 (2)'. 
Article 3 
This  Directive  is  addressed  to  the  Member States. 
Done at  Brussels,  2  May  1978. 
For  the  Council 
The  President 
K. B.  ANDERSEN - 41-
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COUNCIL DECISION 
of 20 May 1975 
settin~~: up a pharmaceutical committee 
(75/320/EEC) 
Tm: COUNCil. OF THE EUROPEAN COMMUNITIES, 
Having  regard  to  the  Tre:tty  establishing  the 
European Economic Community; 
Having regard ro the proposal from the Commission; 
Whereas the implementation of the measures adopted 
by  the  Council  as  regards the approximation of the 
laws  relating  ro  proprietary  medicinal  products  for 
human  use  may  raise  problems  which  should  he 
jointly examined; 
Whereas,  to  this  end,  a  Committee  should  he  set 
up,  chaired  by  a  representative  of  the  Commission 
and  composed  of  representatives  of  the  Member 
States from those States' administrations, 
HAS DECIDED  AS  FOLLOWS: 
Article  1 
A  Committee called  the 'Pharmaceutical  Committee' 
shall be set up and attached to the Commission. 
Article  2 
Without  prejudice  to  the  tasks  of  the  Committee 
for  Proprietary  Medicinal  Products  referred  to · in 
Article 8 of the Second Council Directive 75/319/EEC 
(')  of  20  May  1975  on  the  approximation  of 
provisions  laid  down  by  law,  regulation  or 
administrative  action  relating  to  proprietary 
medicinal  products, the task of this Committee shall 
be to examine: 
- any  question  relating  to  the  application  of 
Directives  on  proprietary  medicinal  products 
which  are  brought up by its Chairman - either 
(•)  See page 13 of this Official Journal. 
on  his  initiative  or  at  the  request  of  the 
representative of a Member State; 
any  other  question  in  the  field  of  proprietary 
medicinal  products  brought up  by  irs  Chairman 
- either  on  his  initiative  or  at  the  requt"st  of 
the representative of a Member Stare. 
The Commission  shall  consult the Committee when 
preparing  proposals  for  Directives  in  the  field  of 
proprietary  medicinal  products,  and  in  particular 
when  it  considers  any  amendments  to  Council 
Oirective  65/6.5/F.F.C (2)  of  26  .January  196S  on  the 
approximation  of  provisions  laid  down  hy  law, 
regulation  or  administrative  action  relating  to 
proprietary  medicinal  products  which  it  might  have 
occasion to propose. 
Article  3 
I.  The Committee shall  consist of senior lxpcrts in 
public  health  matters  from  the  Member  States' 
administrations  and  each  Member  State  shall  have 
one representative. 
2.  There shall be one deputy for each representative. 
This  deputy  shall  be  entitled  to  participate  in 
meetings of the Committee. 
3.  A  rrprcsentative  of  the  Commission  shall  chair 
the Committee. 
Artide 4 
The Committee sho.ll adopt its rules of procedure. 
Done at Brussels, 20 May 1975. 
(1)  ,OJ No 22, 9.  2.  1965, p  . .169/liS. 
For the Co11ncil 
The President 
R.  RYAN - 43-
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COUNCIL DIRECTIVE 
of 12  December 1977 
on the approximation of the laws of the Member States relating to the colouring 
matters which may be .added to medicinal products 
(78/25/EEC) 
THE COUNCIL OF THE  EUROPEAN 
COMMUNITIES, 
Having regard to  the Treaty establishing the European 
Economic  Community,  and  in  particular Article  100 
thereof, 
Having regard  to  the proposal  from  the  Commission, 
Having  regard  to  the opinion of  the  European  Parlia-
ment (1), 
Having  regard  to  the  opinion  of  the  Economic  and 
Social  Committee (2), 
Whereas the  primary purpose of any  laws  concerning 
medicinal  products  must  be  to  safeguard  public 
health ;  whereas,  however,  this  objective  must  be 
attained by  means which will  not hinder the develop-
ment of the pharmaceutical industry or trade in  medi-
cinal  products  within  the  Community ; 
Whereas,  although  the  Council  Directive  of  23 
October  1962 (3),  as  last  amended  by  Directive 
76/399/EEC (4),  established  a  single  list  of  c;olouring 
matters  authorized  for  use  in  foodstuffs  intended  for 
human consumption, the disparities between  the  laws 
of  Member  States  concerning the colouring of  medi-
cinal  products  still  exist ;  whereas  certain  Member 
States apply the rules laid down for foodstuffs to medi-
cinal  products ;  whereas  others  have  separ~te lists  of 
authorized  colouring  matters  for  medicinal  products 
and  for  foodstuffs ; 
( 1)  0 J No  C  62,  30.  5.  1974,  p.  23. 
(') OJ No  C  116,  30.  9.  1974,  p.  24. 
(') OJ No  115,  II. II. 1962,  p.  2645/62. 
(4)  OJ No  L  108,  26.  4.  1976,  p.  19. 
Whereas these disparities tend to hinder trade in medi-
cinal  products  within  the  Community  and  trade  in 
colouring  matters  which  may  be  added  to  these 
products ;  whereas  such  disparities  therefore  directly 
affect  the  establishment  ·and  functioning  of  the 
common  market ; 
Whereas  experience  has  shown  that  on  health 
grounds there is  no reason why the colouring matters 
authorized  for  use  in  foodstuffs  intended  for  human 
consumption should not also  be authorized for  use  in 
medicinal products ; whereas, consequently, Annexes I 
and  III  to  the  Directive  of 23  October  I 962,  as  they 
stand  or  as  they  subsequently  may  be  amended, 
should also  apply  for  medicinal  products ; 
Whereas when  the  use  of a colouring matter in  food-
stuffs and medicinal products is  prohibited in order to 
safeguard  public  health,  technological  and  economic 
disturbances  should  be  avoided  as  far  as  is  possible ; 
whereas  to  this  end a  procedure  should  be  provided 
which  establishes  close  cooperation  between  the 
Member  States  and  the  Commission  within  a 
Committee for  the adjustment to technical progress of 
the Directives on the elimination of  technical barriers 
to  trade  in  the sector of colouring matters which  may 
be  added  to  medicinal  products ; 
Whereas  special  consideration  must  be  given  to 
certain  colouring  matters  hitherto  permitted  by 
certain  Member  States,  in  particular  for  colouring 
medicinal  products  for  external  use, - 44-
HAS  ADOPTED' THIS  DIRECfiVE : 
Article  1 
Member  States  shall  not  authorize,  for  the  colouring 
of medicinal products for human and veterinary use  as 
defined  in  Article  I  of  Council  Directive  65/65/EEC 
of  26  January  1965  on  the  approximation  of  provi-
sions  laid  down  by  law,  regulation  or  administrative 
action  relating  to  proprietary  medicinal  products (1  ), 
any  colouring  matters  other  than  those  covered  by 
Annex  I,  Sections  I  and  II,  to  the  Directive  of  23 
October  1962  as  subsequently  amended.  Any  transi-
tional  provisions  laid  down  for  certain  of  these 
colouring  matters  shall  also  apply. 
Article 2 
Member  States  shall  take  all  measures  necessary  to 
ensure that the colouring matters covered  by Annex I, 
Sections I and II, to  the Directive of 23  October 1962 
satisfy  the general  and  specific  criteria  of  purity  laid 
down  in  Annex  III  to  that  Directive. 
Article 3 
The  methods  of  analysis  needed  to  verify  that  the 
general  and  specific  criteria  of  purity  adopted 
pursuant to the Directive of 23 October 1962 are satis-
fied  shall  also  apply for  the  purpose of  this  Directive. 
Article 4 
Where a colouring matter is  deleted  from  Annex I to 
the  Directive  of  23  October  I 962  but the  marketing 
of  foodstuffs  containing  this  colouring  matter  is 
permitted to  continue for  a limited period, this provi-
sion  shall  also  apply  to  medicinal  products.  This 
limited  period  of  use  may  however  be  amended  for 
medicinal  products  according  to  the  procedure  laid 
down  in  Article  6. 
Article  5 
I.  A  committee  for  the  adaptation  to  technical 
progress of  the  Directives on the elimination of tech-
nical  barriers  to  trade  in  the  sector  of  colouring 
matters  which  may  be  added  to  medicinal  products, 
hereinafter  called  the  'Committee',  is  hereby  set  up 
and  shall  consist  of  representatives  of  the  Member 
States  with  a  representative  of  the  Commission  .as 
chairman. 
2.  The  Committee  shall  draw  up  its  own  rules  of 
procedure. 
Article  6 
I.  Where the procedure laid down  in  this Article is 
to  be  followed,  matters  shall  be  referred  to  the 
(I) OJ No 22,  9.  2.  1965,  p.  369/65. 
Committee by  the chairman, either on his own  initia~ 
tive  or  at  the  request  of  the  representative  of  a 
Member State. 
2.  The  Commission  representative  shall  submit  a 
draft  of the  measures  to  be adopted. The Committee 
shall  deliver  its  opinion  on  such  measures  within  a 
time  limit  set  by  the  chairman  according  to  the 
urgency of the matter. Opinions shall  be delivered by 
a majority of 41  votes, the votes of the Member States 
being weighted  as  provided  in  Article  148  (2)  of  the 
Treaty. The chairman  shall  not vote. 
3..  The  Commission  shall  adopt  the  proposed 
measures  where  they  are  in  accordance  with  the 
opinion  of  the  Committee. 
If  these  measures  are  not  in  accordance  with  the 
opinion of the  Committee, or if  the  Committee does 
not deliver  an  opinion, the  Commission  shall  forth-
with  submit to  the  Council  a  proposal  regarding  the 
measures  to  be  adopted. 
The  Council shall  act  by  a qualified  majority. 
If the  Council  has  not  taken  a decision  within  three 
months of the matter being referreri to it, the Commis-
sion  shall  adopt  the  proposed  measures. 
Article  7 
I.  Member  States  shall  bring  into  force  the  laws, 
regulations  and administrative  provisions  necessary  to 
comply  with  this  Directive  within  18  months  of  its 
notification  and  shall  forthwith  inform  the  Commis-
sion  thereof. 
2.  However,  any  Member State  may  permit, on  its 
own  territory,  until  the  end  of  a  period  of four  years 
from  the  notification  of this  Directive, the  marketing 
of  medicinal  products  containing  colouring  matters 
which  do  not  comply with  the  requirements  of  this 
Directive so long as these colouring matters were auth-
orized  in  that  Member  State  before  the  adoption  of 
the  Directive. 
3.  Depending  on  the  opm10n  of  the  Scientific 
Committee for  Food and of the Committee referred to 
in  Article  5  the  Commission  shall  if  appropriate 
submit to  the  Council  within  two  years  of  the  adop-
tion of this Directive a proposal for amendment of the 
Directive  to  allow  the  use  of: 
the  colouring  matters : 
=  Brilliant  Blue  FCF  CI  42090, 
=  Red  2G  CI  18050, 
other colouring matters for  medicinal products for 
external  use  only. 
The Council shall take a decision on the Commission 
proposal  no  later than  two  years  after  its  submission. - 45-
4.  Member  States  · shall  communicate  to  the 
Commission  the  text  of  the  main  provisions  of 
national  law  which they adopt in  the  field  covered by 
this  Directive. 
Article 8 
This  Directive  is  addressed  to  the  Member States. 
Done at  Brussels,  12  December  1977. 
For the  Cou11cil 
The  Pre.ridm t 
A.  HUMBLET - 46-
LIST OF  COLOURmG  ldATERIALS 
AUTHORISED  FOR  COLOURING  MEDICINAL  PRODUCTS 
UP  TO  1.1.1978 
(Annex  I,  sections  I  and II of the Directive of October 23,  1962*) 
No. 
E100 
E 101 
E 102 
E 104 
E llO 
E 120 
E 122 
E 123 
E 124 
E 127 
E  131 
E  132 
E 140 
E 141 
E 142 
E 150 
E 151 
E 153 
Common  Name 
Our cumin 
Lactoflavin  (Riboflavin) 
Tartrazine 
Quinoline yellow 
Orange  yellow S  sunset yellow FCF 
Cochineal  carminic acid 
Azorubine  Carmoisine 
Amaranth 
Cochineal Red  A Ponceau  4R 
Eryi;hrosine 
Patent  Blue  V 
Indigot in (indigo  carmine) 
Chlorophylls 
Copper  complexes  of  chloropbwlls and chlorophyllins 
Acid brilliant green  BS  (lissamine green) 
Caramel 
Brillant  Black  EN,  Black PN 
Carbo  medicinalis vegetalis  (charcoal) 
*  Council Directive of  23  October 1962  concerning the approximation of 
legislation of Member  States concerning colouring materials which  can 
be utilised in foodstuffs destined for human  consumption - OJ  115 of 
llellel962,  P•  2645/62 
amended by  : 
-Directive 65/469/EEC  of 25  October 1965- OJ  178 of 26.10.1965,  p.2793/65 
-Directive 67/653/EEC  of 24  October 1967- OJ  263  of 30.10.1967,  P•  4 
-Directive 68/419/EEC  of 20  December  1968- OJ  L 309  of 24.12.1968,  P•  24 
- Directive 70/358/EEC of 13  July 1970 - OJ  L 157  of 18.7.1970,  P•  36 
- Act  of Accession  - OJ  L 73  of  27 .3.1972,  P•  14 
- Directive 76/399/EEC  of 4 April 1976 - OJ  L 108 of 26.4.1976,  P•  19 
- Directive 78/144/EEC  of 34  January 1978  - OJ  L 44  of 15.2.1978 No. 
El6o 
E  161 
E  162 
E  163 
E  170 **) 
E  171  **) 
E  172 **) 
E  173 **) 
E  174 **) 
E  175 **) 
- 47-
Common  Name 
Carotenoids  : 
a)  Alpha-, beta-,  gamma-carotene 
b
0
)  Bixin, Nor  bixin ( Roucou  .Annatto) 
)  Capsanthin,  Capsorubin 
d)  l{y'copene 
e)  Beta-apo-8'  carotenal (c 30) 
f)  ~hyl ester of beta-apo-8'  carotenoic acid (C  30) 
Xa.nthophylls 
a)  Flavoxa.nthin 
~~ 
d) 
e) 
f) 
g) 
Lu~ein 
Kryptoxa.nthin 
Rubixanthin 
Violoxanthin 
Rhodoxant 
Canthaxanthin 
Beetroot  red, betanin 
An tho  cyan  ins 
Calcium  carbonate 
Totanium dioxide 
Iron oxides and hydroxides 
Aluminium 
Silver 
Gold 
**)  Fo'r  surface co louring only  • - 49-
COMMITTEE  FOR  PROPRmi'ARY  MEDICINAL  PRODUCTS 
rules of procedure 
THE  COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS, 
Having regard to  Council  Directive 75/319/EEC  of  20  May  1975 on  the 
approximation of provisions laid down  by  law,  regulation or administrative 
action relating to proprietar,y medicinal products,  and  in particular 
Article 8(3)  thereof,  (1) 
HAS  DRAWN  UP  ITS  RULES  OF  PROCEDURE  AS  FOLLOWS  : 
(1)  OJ  No  L 147,  9.6.75 -50-
.Article  1~ 
1. The  Committee  shall consist of one  repr-esentative for each Member  State 
and one  representative of the  Commission.  One  alternate shall be appoint-
ed for each of the representatives. 
2.  The  Committee  members  and the alternates shall be appointed by the Member 
States for three years provided the,y  continue to be national officials 
responsible for examining applications for authorization to market  pro-
prietar,y medicinal products.  Their appointments shall be renewable. 
3. An  alternate shall sit in this capacity on the Committee  on~ if the 
fUll  member  is absent  or is unable to discharge his duties. 
4.  Each  representative may  arrange to be accompanied at  Committee  meetings 
by not  more  than three experts  • 
5.  Even after their duties have  ceased,  members,  alternates and experts 
shall be required not to disclose information of the kind covered by the 
obligation of professional secrecy. 
Article 2 
The  Committee  shall elect its Chairman  from among  its members  by absolute 
majority and secret ballot.  If, after two  ballots,  nobo~ has obtained an 
absolute majority of the votes,  the member  who  obtains the relative majority 
at the third ballot shall be elected.  In  ~ihe  event  of a  tie the oldest 
candidate shall be declared elected. 
Article 3 
The  term of office of the  Chairman  shall be three years.  He  shall be eligible 
for re-election once only. 
Article 4 
As  soon  as he takes up  ~is duties, the Chairman  shall cease to be a 
representative and shall be replaced in tha.t  capacity. 
Article 5 
Two  Deputy  Chairmen  shall be appointed to replace the  Chairman  when  he is 
absent  or unable to discharge his duties.  One  shall be  elected by the 
Committee  and the other appointed by the  Commission. 
The  provisions of Articles 2  and  3 of these Rules of Procedure  shall apply 
to the  election and the term of office of the elected Deputy  Chairman. -51-
Article 6 
The  Committee  shall be  convened by its Chairman,  either on his own  initiative 
or at the request  of a  member. 
Article 7 
The  Chairman  shall draw  up  the agenda,  in which distinctions shall be  made 
between  : 
a)  objections to applications for marketing authorizations submitted to 
the Committee for an  opinion under Article 11  (1)  of Directive 75/319/EEC; 
b)  refusals,  suspensions or revocations of marketing authorizations submitted 
to the Committee for an opinion under Article 12  (2)  of Directive 
75/319/EEC; 
c)  fresh examinations of previous opinions under Article 13 of Directive 
75/319/EEC; 
d)  specific cases submitted under Article 14 of Directive 75/319/EEC. 
Article 8 
Requests to  convene the Committee  which are made  by a  member  must  be  drawn 
up in accordance with the classification set out  iri the foregoing Article 
and be reasoned such that they may  constitute the working paper of the 
Committee. 
Article 2 * 
1. Pursuant to Article 9  (1)  of Directive 75/319/EEC,  the Member  state 
concerned shall forward to the Committee  a  dossier containing : 
a)  a  cop,y  of the request for forwarding to the competent authorities 
of the Member  States specified; 
b)  a  copy  of the marketing authorization; 
c)  the particulars and documents  listed in the second paragraph of 
Article 4  of Directive 65/65/EEC. 
There  shall be forwarded as many  dossiers as there are Member  States 
specified,  plus one for the secretariat  of the Committee. 
2.  Pursuant to Article  9  (2)  of Directive 75/319/EEC,  the Committee  shall 
forthwith forward this dossier to the competent  authorities of the Member 
States specified. 
3.  The  Committee  shall send to the members  of the  Committee the documents 
referred to in paragraph 1  (a)  and  (b)  above. 
*  To  be amended  cf  •  Council Directive 7  8 / 420/EEC  of 2nd  May  197 8. -52-· 
Article 10 
The  dossier kept  by the secretariat of the Committee  may  be consulted by any 
member  of the Committee  or by the experts referred to in Article 1  (4)  having 
the written authority of the member. 
Article 11 
1. The  notification of the meeting,  the agenda and the working papers shall 
be forwarded by the  Chairman  to the members  of the  Committee  in accordance 
with the procedure laid down  in Article 18 (2)  and  (3). 
2.  These  papers shall be delivered to the Permanent  Representatives of the 
Member  States and to the  Commission  not  later than fifteen days before 
the date of the meeting. 
3. In urgent  cases, the  Chairman  may,  at the request  of'  a  member  of'  the 
Committee  or on  his own  initiative,  shorten this period of notice by up 
to three clear working days,  stating the grounds for his decision. 
Article 12 
1. Meetings of the Committee  shall be  valid~ held if six Member  states are 
represented. 
2.  The  representative of a  Member  state may,  if necessary,  undertake the 
representation of one  other Member  state.  The  Chairman  of the Committee 
shall be informed  according~ by the Permanent  Representative of the 
Member  State wishing to be  so  represented. 
Article 13 
The  Committee  may  convene  panels of experts to  study matters of  common 
interest. 
Article 14 
The  secretariat services for the  Committee  shall be provided by the  Commission, 
assisted, if  necessar.y,  by experts. 
Article 15 
1. The  Member  states concerned shall be  informed forthwith of the reasoned 
opinions delivered pursuant to Articles 11  and 12  of Directive 75/319/EEC 
in accordance with the procedure set  out  in the first  subparagraph of' 
Article 18  ( 2) • -53-
2. A summary record shall be prepared UDder  the responsibility _of  the 
Chairman for each meeting;  it shall be forwarded to the members  of the 
Committee  in accordance with the procedure set out  in Article 18 (2)  and 
( 3).  Any  comments  which the members  rmw  wish to make  shall be coDIJIIlDl.icat-
ed.  to the Chairman in writing.  'lhe Chairman  shall pass them on to the 
Committee;  if there is disagreement, the proposed amendment  shall be 
discussed at the following meet~g.  If disagreement persists, this 
amendment  shall be appended to the relevaD.t  record. 
Article 16 
The  Chairman of the Committee  shall act as  pro~ for the Committee to perform 
the formal recording referred to in Article 10 (1)  of Directive 75/319/EEC. 
He  shall forthwith inform the Member  states of this formal recording in 
accordance with the procedure set out  in the first paragraph of Article 
18 (2). 
Article 17 
1. 'Ihe  secretariat of the Committee  shall act as  pro~ for the Committee to 
forward the dossier referred to in Article 9  ( 2)  to the competent 
authorities of the Member  states in accordance with the procedure set out 
in the first paragraph of Article 18 (2)  and,  in. the same  way,  the 
documents referred to in Article 9 (3). 
2. The  information forwarded to the Committee  in accordance with Article 
11  (3), Article 12  (4)  and Article 33 of Directive 75/319/EEC shall be 
brought to the knowled&e  of the members  of the Committee by the secre-
tariat in accordance with the procedure set out in the second paragraph 
of Article 18 (2). 
Article 18 
1. Correspondence of concern to the Committee  shall be addressed to the 
secretariat of the Committee,  Directorate-General for Internal Market 
and Industrial Affairs, for the attention of the Chairman. 
2.  Correspondence intended for the representatives of the Member  states 
shall be addressed to the Permanent  Representations. 
Copies of such correspondence shall be addressed directly to the 
representatives of the Member  States. 
3.  Correspondence  intended tor the representative of the Comission shall 
be addressed to the Commission,  Directorate-General for Internal Market 
and Industrial Affairs. -54-
Article 19 
Notwithstanding the  prov~s~ons of Article 214  of the Treaty,  the work  of 
the Committee  and of the panels of experts and all the documents  submitted 
to them  shall be treated as confidential.  Nevertheless, the representatives 
of the Member  States may,  in accordance with the national laws  in force, 
inform the person responsible for marketing a  medicinal product  or products 
of the reasoned objection of a  Member  State, as referred to in Article 10 (2) 
of Directive 75/319/EEC. No C 302/6 
-55-
Official Journal of the European Communities 
Notice to applicants for marketing  authorizations  for  proprietary  medicinal  products 
I. A new procedure for placing proprietary medicinal products on the market 
Following the European Community Directives adopted in 1975 (Offidal journal of 
the  European  Communities  No L 147  of 9  June  1975)  all  manufacturers  of  and 
persons  responsible for  marketing proprietary medicinal products  may  now  use  a 
new  procedure for  placing their  products  on the  markets  of the  Member States: 
they  may go  through the  Committee for  Proprietary  Medicinal  Products  attached 
to the Commission of the European Communities in Brussels. 
II.  Conditions to be fulfilled in order to use this procedure: 
1.  The  proprietary  medicinal  product  in  question  must  first  have  obtained  a 
marketing  authorization  (subsequently  referred  to  as  M.A.)  in  one  of  the 
Member  States,  as  laid  down  in  Directives  65/65/EEC,  75/318/EEC  and 
75/319/EEC.  . 
Vaccines,  toxins  and  serums,  proprietary  medicinal  products  based  on  human 
blood or blood constituents,  radioactive  isotopes  and  homeopathic proprietary 
medicinal products may  not benefit from  this  procedure (Article 34 of  Directive 
75/319/EEC). 
2.  Applications  for  M.A.  via  the  Committee  must  relate  to  at  least  five  other 
Member States. 
III.  Procedure to be  followed: 
(a)  Documents  to be  supplied  to the  competent  authority  of  the  Member  State 
which has granted the initial M.A.: 
1.  Request that the  documents  be  forwarded  to  at ieast  five  named  Member 
States through the Committee for Proprietary Medicinal Products; 
2.  Information and documents  listed  in  the  second  paragraph  of  Article  4  of 
Directive 65/65/EEC; 
3.  Copy of the M.A. 
(b)  The  number  of  copies  of  these  documents  to  be  supplied  is  one  for  each 
Member State concerned plus one for the Committee secretariat. 
(c)  The languages in which the documents must be presented: 
1.  The documents referred to in tht second paragraph of Article 4 of Directive 
65/65/EEC must be provided in one of the official languages of each  of  the 
Member States concerned; except that the documents referred to in  item  8 
of the second paragraph of Article 4 may, alternatively, be presented in: 
- English for Germany, 
- English for Belgium, 
- English, French or German for Denmark, 
- English or French for Italy, 
- Dutch, English, German or Italian for Luxembourg, 
- English, French or German for the Netherlands. 
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2.  The  copy  intended  for  the  Committee  secretariat  may  be  in  English  or 
French. 
(d)  No special fee is payable to the Committee for Proprietary Medicinal Products, 
but national registration fees  remain applicable. 
(e)  A reasoned  opinion  of  the  Committee,  which  will  be  based  on  information 
contained in the application for  an  M.A  .. , shall  not be  regarded as  an  M.A.  in 
any  Member State. 
IV.  Consideration of divergent decisions: 
Directive  75/319/EEC  also  makes  provision  for  consideration  by  the  Committee 
of divergent  decisions  taken  by  the  Member  States  as  regards  the  authorization, 
suspension or revocation of an M.A. 
Any one of the Member States concerned may request the opinion of the Committee 
concerning the grounds for refusal, suspension or revocation of the M.A.  as  given 
by the authorities of another Member State. 
Within 30 days,  the Member States shall  notify the  Committee of the action they 
intend to take following the opinion. 
V.  Force of the opinions of the Committee: 
The opinions of the Committee shall  not be  binding on Member States  and shall 
not replace national decisions. 
VI.  Additional information: 
For  additional  information,  please  apply  to  the  Secretariat,  Committee  for  Pro-
prietary  Medicinal  Products,  3  Rond-Point  Schuman,  B-1049  Brussels;  or· to  the 
appropriate national licensing authority. -57-
COMMITTEE  FOR  PROPRIETARY  MEDICmAL  PRODUCTS 
Application for marketing authorization for 
a  proprietar.y medicinal product 
-The  Committee  for Proprietar.y Medicinal specialities wishes  in respect  of 
Council Directives 65/65/EEC,  75/318/EEC  and 75/319/EEC that the particulars 
in support of applications for authorizations to place proprietar,y medicinal 
products on  the market  are presented in the following way  in order to 
facilitate the task of the applicants and the competent  authorities. -58-
Flyleaf 
1. Na.me  or business name  of applicant  fo:r  marketing authorization 
2. Full address 
3. a)  Name  and address of manufacturer 
b)  Name  and address  of'  importer 
4.  Name  of the proprietar,r medicinal  product 
5. Pharmaceutical f'orm 
6. Me.thod  and route of administration 
7•  Number  of annexes  supplied in support  of the application -59-
Annex  I  :  General  Information 
- Name  of the proprietar,y medicinal product 
- Pharmaceutical form 
- Qualitative and quantitative composition in terms  of active principles 
- Therapeutic indications 
- Dosage 
- Contra-indications 
- Warnings  and precautions  (including during pregnancy) 
- Side-effects 
- Directions for use  (where applicable) 
- Shelf life and  storage precautions - 60-
Annex II  fn!o~t,!o~ ~~  ~~~t!  ~!!o!~~g_p~!i~o:c!:e!!!i~a,!, 
£i212g!o!l_o£ ~i2r2b!o!o~i~! !e!t! 
- Name  of product 
- Composition 
Names  of constituents  Quantity  Ref"erence to 
standards 
Active principles 
other constituents 
- Container (brief description) - 61-
1. Manufacturing formula 
2. Manufacturing process  including in-process control and the pharmaceutical 
assembly process -~-
1. Active principles 
a)  Active principles described in a  pharmacopoeia 
b)  Active principles not  described in a  pharmacopoeia - 63-
2. other constituents 
a)  Constituents described in a  pharmacopoeia 
b)  Constituents not  described in a  pharmacopoeia - 64-
Annex  II D  .£o!:t::o! !e!t! ,2n_l.!:t~~i!t! Er.2d~C!s_ 
(if necessary) - 65-
1. General characteristics, other quality control tests required by the 
nature of the product; 
(appearance,  dimension,  shape,  colour,  odour,  distinguishing features, 
etc.) -~-
2. Identification and quantitative determination of the active principle or 
principles, other quality control tests, with a  description of the 
methods  employed  (including, if necessar,y,  and  depending on  the nature 
of the product, biological and microbiological methods). - 67-
3. Identification and quantitative determination of the other constituents 
(if necessary) -~-
1. Proposed shelf life (depending on  tl1e  type of container) 
2.  Information concerning stability,  n1cluding physical stability 
- number  of batches tested 
- storage conditions 
- methods  employed 
- description of containers -~-
3. Results and interpretations Annex  II G  Conclusions  ------
Certificate by the expert  analyst  on  the application of the methods  and 
justification of the control methods to be used by the manufacturer - 71-
Annex  III  !o~i~o!o~i~a! ~~  ~h~~o!o~i~a!  ~e!t! * 
(Summary  of the tasks performed by the expert  pharmacologist) 
The  following information must  be provided in respect  of  each test  : 
1. Animals  used  (species,  strain,  ~ex, etc.) 
2.  Experimental  conditions  including diet 
3. Results 
* If use is made  of a  list of published references pursuant to point  8 
of the  second paragraph of Article 4 of Council  ~rective 65/65/EEC 
(OJ  No  22  of 9 February 1966) ,  the expert  must  show  that this is 
justified. Annex  III 
1. Subacute toxicity trials - 73-
Annex III 
2.  Chronic toxicity trials - 74-
.Annex III 
b
a)  tests for teratogenicity (dosing during period of organogenesis) 
)  pre- and postnatal dosing of the mother to demonstrate  effects on 
late pregnancy,  parturition and lactation - 75-- 76-- 77-
Annex III F  Pharmaco~amics 
1. Actions  releVant to the proposed therapeutic uses 
2. Other actions  investigated 
3.  Interactions - 78-
Annex  III G  Pharmacokinetics  ---------
1. Absorption  (serum  levels of the medicb1al  product) 
2. Distribution of the medicinal  product 
3. Biotransformation 
4.  Excretion of the medicinal product  or metabolites - 79-
.Annex  IV  Clinical trials * 
...___.._. ____ _ 
(Summary  of the tasks performed by the expert  clinician) 
* If use is made  of a  list of  published references pursuant to point  8  of 
the  second paragraph of Article 4 of  Council  Directive  65/65/EEC 
(OJ  No  22  of  9 February 1965),  the expert  must  show  that this is justified. - 80  --
Annex  IV  Clinical trials  --------
1. Individual data - clinical reports - 81-
Annex  IV  Clinical trials  --------
2.  Summary - 82-
Annex  IV  Clinical trials  --------
Annex  IV  B  Clinical data  -------
3.  Conclusions - 83-
Annex  IV  Clinical trials 
Information on  side-effects and interactions observed when  used in other 
countries  (the extent  of usage  in terms of number of prescriptions and 
duration of use is useful in assessing the frequenqy  of the adverse reaction) - 84 -· 
Annex  V 
1. Packaging 
2. Label 
3. Package  insert - 85-
/ 
Annex  V B  ¥B.!!!P.!e!! 
I 
I 
I 
I -86-- 87-European Communities- Commission 
The rules governing medicarnen1S in the European Community 
luxembourg: Office for Official Publications 
of the European Communities 
1978-88 p.- 17,6 x 25 em 
DA, DE, EN, FR, IT, Nl 
ISBN 92-825-0275-9 
Catalogue number: CB-24-78-120-EN-C 
BFR 190 
LIT 5100 
DKR 33,50 
HFL13 
OM 12,20 
UKL3.25 
FF 27 
USD 5.90 
The  conditions  in  which  proprietary  medicinal  products  can  be  manu-
factured  and  marketed  within  various  Member  States  of  the  European 
Communities are regulated by Community rules which are  contained in a 
number  of  Directives.  These  texts  afford  protection  on  the ground of 
public health  and  improve the  free  movement of medicines.  As  regards 
public  health,  this  protection  is  designed  to ensure  that  medicines  are 
soundly based and of high quality of manufacture. 
To  facilitate  free  movement of  medicines  a Committee for Proprietary 
Medicinal  Products  has  been  set up to ensure close  co-operation between 
the  competent  authorities  of  the  nine Member States so  that decisions 
made  upon  applications  for marketing authorization are  as  consistent as 
possible.  Another  factor  in  facilitating  free  movement of medicines  is 
the suppression of regular controls at the time of importation. Salgs- og  abonnementskontorer  ·  Vertriebsburos  ·  Sales  Offices 
Bureaux de vente  ·  Uffici di  vendita  ·  Verkoopkantoren 
Belgique - Beigie 
Moniteur beige- Belgisch Staatsblad 
Rue  de  Louvain  40-42 -
Leuvensestraat 40-42 
1  000 Bruxelles  - 1  000 Brussel 
Tel.  5120026 
CCP  000-2005502-27 
Postrekening 000-2005502-27 
Sous-dep6ts - Agentschappen: 
Librairie  europeenne - Europese 
Boekhandel 
Rue  de  Ia  Loi  244 - Wetstraat 244 
1040 Bruxelles - 1  040 Brussel 
CREDOC 
Rue  de  Ia  Montagne 34 - Bte  11 
Bergstraat 34 - Bus  11 
1  000 Bruxelles - 1  000 Brussel 
Dan  mark 
J.H. Schultz-Boghandel 
MQintergade  19 
111 6  KQibenhavn  K 
Tlf.  (01)141195 
Girokonto 200 1195 
Underagentur: 
Europa  Bfllger 
Gammel Torv 6 
Postbox  137 
1  004 KQibenhavn  K 
Tlf.  (01) 145432 
BR Deutschland 
Verlag Bundesanzeiger 
Breite  StraBe - Postfach  10 80 06 
5000 Koln  1 
Tel.  (0221) 210348 
(Femschreiber:  Anzeiger Bonn 
8 882 595) 
Postscheckkonto  834 00 Koln 
France 
Service  de  vente  en  France  des  publica-
tions des  Communautes europeennes 
Journal officiel 
26, rue  Desaix 
75732 Paris  Cedex  15 
Tel.  (  1  I 5  78 61  39 - CCP  Paris  23-96 
Sous-agent 
D.E.P.P.  - Maison de  I'Europe 
37,  rue  des  Francs-Bourgeois 
75004 Paris 
Tel.:  887 96 50 
Ireland 
Government Publications 
Sales  Office 
G.P.O.  Arcade 
Dublin  1 
or by post from 
Stationery Office 
Beggar's  Bush 
Dublin  4 
Tel.  688433 
ltalia 
Libreria della Stato 
Piazza  G.  Verdi  1  0 
00198 Roma  - Tel.  (6)  8508 
Telex  62008 
CCP  1/2640 
Agenzia 
Via  XX Settembre 
(Palazzo  Ministero del tesoro) 
00187 Roma 
Grand-Duch6 
de Luxembourg 
Office des publications offlcielles 
des  Communaut!Js europiJennes 
5,  rue  du  Commerce 
Boite postale  1  003 - Luxembourg 
Tel. 490081- CCP  19190-81 
Compte courant bancaire: 
BIL 8-109/6003/300 
Nederland 
Staatsdrukkerij- en uitgeverijbedrijf 
Christoffel  Plantijnstraat, 's-Gravenhage 
Tel.  (070)  62 45 51 
Postgiro 42 53 00 
United Kingdom 
H.M. Stationery Office 
P.O.  Box  569 
London  SE1  9NH 
Tel.  (01) 928 69 77, ext.  365 
National  Giro  Account  582-1002 
United States of America 
European Community Information 
Service 
2100 M  Street, N.W. 
Suite 707 
Washington,  D.C.  20 037 
Tel.  (202) 862 9500 
Schweiz - Suisse - Svizzera 
Librairie Payot 
6,  rue  Grenus 
1211  Geneva 
Tel.  3189 50 
CCP  12-236 Geneva 
Sverige 
Libralrie C.E. Fritze 
2,  Fredsgatan 
Stockholm  16 
Postgiro  193, Bankgiro 73/4015 
Espafta 
Ubrerla Mundi-Prensa 
Caste116  37 
Madrid  1 
Tel.  275 46 55 
Andre  Iande  ·  Andere  Under  ·  Other  countries  ·  Autres pays  ·  Altri  paesi  •  Andere Ianden 
Kontoret for De  europmiske  F111llesskabers  officielle  Publikationer  •  Amt fiir amtliche Ver6ffentllchungen der Europllschen Gemelnschaften  •  Office for 
Official  Publications  of the  European  Communities  •  Office  des  publications  offlcielles  des  Communaut6s  europ6ennes  •  Ufficio  delle  pubblicazioni 
ufficiali· delle Comunita europee  •  Bureau  voor offlciile publikaties der EuropeJe Gemeenschappen 
Luxembourg  5,  rue  du  Commerce  Batte  postale  1  003  T61.  49 00 81  CCP  19 190-81  Compte  courant  bancalre  Bl C 8-1 09/6003/300 
i  :--BFA 190  DKA 33,60  OM 12,20  FF 27  LIT 6 tOO  HFL 13  UKL 3.26  USO 6.90 
A  OFFICE FOR OFFICIAL PUBLICATIONS 
... OF  THE  EUROPEAN  COMMUNITIES 
Boite postale 1  003 - Luxembourg 
ISBN 92-825-G275-9 
Cetalogue nutnber: CB-24-78-120-EN-C 